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The 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics international conferences, and the 2010 Annual 
Meeting of The Antibody Society, organized by IBC Life Sciences with contributions from The Antibody Society and two Scientific 
Advisory Boards, was held December 5–9, 2010 in San Diego, CA. The conferences featured over 100 presentations and 100 post-
ers, and included a pre-conference workshop on deep-sequencing of antibody genes. The total number of delegates exceeded 800, 
which set a new attendance record for the conference.
The conferences were organized with a focus on antibody engineering only on the first day and a joint engineering/thera-
peutics session on the last day. Delegates could select from presentations that occurred in two simultaneous sessions on days 2 
and 3. Day 1 included presentations on neutralizing antibodies and the identification of vaccine targets, as well as a historical 
overview of 20 years of phage display utilization. Topics presented in the Antibody Engineering sessions on day 2 and 3 included 
antibody biosynthesis, structure and stability; antibodies in a complex environment; antibody half-life; and targeted nanoparticle 
therapeutics. In the Antibody Therapeutics sessions on days 2 and 3, preclinical and early stage development and clinical updates 
of antibody therapeutics, including TRX518, SYM004, MM111, PRO140, CVX-241, ASG-5ME, U3-1287 (AMG888), R1507 
and trastuzumab emtansine, were discussed and perspectives were provided on the development of biosimilar and biobetter anti-
bodies, including coverage of regulatory and intellectual property issues. The joint engineering/therapeutics session on the last 
day focused on bispecific and next-generation antibodies. Summaries of most of the presentations are included here, but, due to 
the large number of speakers, it was not possible to include summaries for every presentation.
Delegates enjoyed the splendid views of the San Diego Bay and proximity to the Gaslamp Quarter provided by the venue. 
The 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics conferences, and the 2011 Annual Meeting of 
The Antibody Society, are planned for December 5–8, 2011 at the same location in San Diego, and will include two two-day 
short courses on Introduction to Antibody Engineering and Protein Characterization for Biotechnology Product Development.
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Neutralizing Antibodies and Identification  
of Vaccine Targets
The first session of the meeting focused on exploiting antibod-
ies for the development of new vaccines. The session chairman, 
Richard Begent (University College London), welcomed delegates 
with the reminder that antibodies are the best way to diagnosis 
infectious disease. He then pointed out that while it was analytical 
techniques that first focused attention on antibodies that targeted 
infectious agents, the field has broadened to include a wide range of 
disciplines, such as genetics. Beginning with hybridoma technol-
ogy (i.e., the formation of hybrid cell lines by fusing an antibody-
producing lymphocyte and a non-antibody producing cancer cell), 
recent technological achievements, such as in vitro isolation of anti-
bodies from combinatorial libraries and their functional expression 
in bacteria, have infused the field with great power. However, this 
capacity may be underutilized unless the targeted biological sys-
tem, as well as the antibody, is fully understood.
The keynote presentation was delivered by Dennis Burton 
(The Scripps Research Institute). Professor Burton began with 
an overview of classical vaccine design and the fact that it does 
not require an understanding of the interplay between patho-
gen and immune system. Unfortunately, chemical inactivation 
or live attenuation are either too cumbersome or ineffective for 
highly variable vaccine targets, such as influenza or the human 
immunodeficiency virus (HIV). Professor Burton described a 
rational structure-based immunogen design effort that requires 
full understanding of the molecular interactions of a broadly neu-
tralizing antibody (bNAb) and antigen. These efforts focus on 
overcoming obstacles created by the immune-evasion capabilities 
of host immune-selective pressures. Reverse engineering a vac-
cine involves the isolation of bNAbs from infected individuals, 
the molecular characterization of bNAb-pathogen antigen inter-
action, subsequent immunogen design and testing, and the even-
tual combination of several immunogens for a vaccine.
The major targets for HIV-1 neutralizing antibodies are the 
envelope glycoproteins (Envs): the exterior Env gp120 medi-
ates receptor binding, and the transmembrane Env gp41 medi-
ates viral entry. To generate an effective neutralizing antibody 
response against HIV-1, it is necessary to target functionally 
conserved, exposed regions of the Envs. With the laborious iso-
lation of b12,1 which was the first HIV-1 bNAb isolated from 
HIV positive donors, the primary receptor CD4-binding site 
(CD4bs) on gp120 became an attractive surface to target for 
focused immunogen design. Professor Burton discussed in vivo 
protection studies demonstrating that b12 protects against low-
dose repeated mucosal simian HIV challenge in macaques2 and 
that Fc-receptor, but not complement binding, is important in 
antibody protection against HIV.3 Attempts to reverse engineer 
the CD4bs epitope have included immunofocusing on gp120 
by hyperglycosylation and mutation, fragmentation of the outer 
domain constructs, peptide reconstruction of CD4bs and epitope 
cloaking.
The other gp120 directed bNAb, 2G12, binds to a cluster of 
conserved glycans on the outer domain of the exterior glycopro-
tein.4 2G12 recognizes the sugars on the gp120 glycan shield by its 
domain-exchanged structure that produces a rigid array of bind-
ing sites. While attempts to exploit the 2G12 epitope as a vaccine 
target using agents such as oligodendrons, protein-glycodendron 
conjugates and oligomannose on virus scaffolds have not elicited 
a neutralizing response, molecular studies on the mechanism of 
domain exchange have revealed a potential immunization strategy.
Professor Burton then discussed use of gp41-directed bNAbs 
2F5 and 4E10 as templates for immunogen design. While both 
bNAbs bind to continuous regions close to the viral membrane, 
2F5 recognizes an extended loop structure and 4E10 binds a heli-
cal epitope conformation.5,6 Efforts to re-elicit 2F5 and 4E10-like 
antibodies using scaffold immunogens in guinea pigs resulted 
in good mimicry, but did not produce neutralizing antibodies.   
Therefore, research is now focused on membrane incorporation 
and the elicitation of hydrophobic character in gp41 immunogen 
design.
Attempts to reverse engineer an HIV-1 vaccine with the 
original four bNAbs had been ongoing for nearly a decade when 
Professor Burton began collaborating with the International 
AIDS Vaccine Initiative (IAVI) to screen donors for new bNAbs 
(i.e., the Protocol G project). Using high throughput technology, 
the scientists at IAVI were able to generate human monoclonal 
antibodies (mAbs) from broadly neutralizing serum donors and 
isolated two elite neutralizers (PG9 and PG16) that have out-
standing breadth and potency. Both PG9 and PG16 neutralize 
approximately 85–90% of viruses in a 160-virus panel and dis-
play a potency of 1–2 logs better than the previous four bNAbs.7 
Most importantly, PG9 and PG16 recognize the V2/V3 variable 
loop epitope and are largely trimer specific. A high-resolution 
crystal structure has been solved and shows an inflexible ham-
merhead structure with a sulfated tyrosine that recognizes the 
virus. Both antibodies display uniquely long CDRH3 arms with 
a variable loop that determines their fine specificity. In addition 
to these new and impressively potent bNAbs, several more novel 
bNAbs are being isolated and tested. Professor Burton optimisti-
cally concluded his presentation by stating that the rate-limiting 
step is no longer the acquisition of bNAbs. The generation of a 
functional immunogen is now the biggest hurdle and the new 
bNAbs give great insight into surmounting this issue.
Kate Williams (University of California, Berkeley) reported 
on the role antibodies play in protection and enhancement of 
dengue virus infection in a mouse model of dengue disease. 
Ms. Williams began with an overview of antibody-dependent 
enhancement (ADE) and an explanation of why a tetravalent den-
gue virus (DENV) vaccine must elicit robust protection against 
all serotypes. There are four serotypes of DENV and infection 
with one serotype is typically asymptomatic and protects against 
re-infection with the same serotype; but secondary infection 
with another DENV serotype carries an increased risk of severe 
disease, including a life-threatening vascular leakage syndrome 
referred to as dengue hemorrhagic fever/dengue shock syndrome. 
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CR8020 and CR8043 protects mice against lethality from H3N2 
challenge and there is mutually exclusive binding by CR6261 
and the new mAbs. Using competition binding experiments and 
computational modeling, a second overlapping conserved epitope 
has been identified in group 2 influenza viruses. These H3 mAbs 
prevent infection through two different mechanisms. They either 
block pH-induced conformational change or prevent proteolytic 
cleavage. Dr. Vogel concluded by reiterating that group 2 mAbs 
have defined a second conserved epitope on HA that is key to virus 
replication and that these H1/H3 mAbs are an important addition 
to the arsenal against influenza.
Twenty Years of Phage Display
The second session of the day, which celebrated the 20 year anni-
versary of the development of antibody phage display, began 
with opening remarks by chairman James Marks (University of 
California, San Francisco). He began with a summary of the cur-
rent state of antibody therapy by stating that all pharmaceutical 
companies now have antibody programs; there are currently 24 
US Food and Drug Administration (FDA)-approved antibody 
drugs with four more undergoing review and hundreds of mAbs 
in clinical studies;12 and the estimated global sales will exceed 
$50 billion by the year 2015. Professor Marks then discussed 
highlights of antibody-based technology development, including 
hybridoma technology, antibody phage display, and transgenic 
mice. He concluded with the reminder that phage display has 
been an invaluable tool in the development of human antibodies 
as research tools and therapeutics.
The first presentation was delivered by the grandfather of 
phage display, George Smith (University of Missouri), and 
detailed the successes and failures of the technology’s develop-
ment and use over the last twenty-two years. Professor Smith 
began with a comprehensive review of filamentous phage and 
the construction of phage display libraries. This technique uses 
recombinant DNA technology to create bacteriophages with a 
peptide or single chain antibody or Fab fused to multiple cop-
ies of a coat protein, thereby displaying it on the phage sur-
face, while DNA encoding the displayed entity is packaged 
within the virion. Phage that bind a target molecule can then 
be identified through affinity selection, which has enabled the 
engineering of peptides, antibodies and other protein domains. 
While the technological advantage of phage display over use 
of animals or mammalian cell culture to generate human anti-
bodies appeared to be clear at the outset, its biggest failure is 
that in the intervening 22 years antibody-library technology has 
not been widely disseminated. Professor Smith then described 
factors inhibiting its wide spread use, including the use of the 
phagemid system rather than phage for antibody display. He 
suggested that, were phage displayed antibody systems further 
upgraded and streamlined, this technology could be accessed 
by “non-specialist” researchers, just as phage-displayed peptide 
libraries are. Professor Smith concluded by stating that even 
though there are drawbacks to phage-displayed antibodies, it 
is still an ingenious innovation that has produced many impor-
tant discoveries.
It has been reported that anti-DENV antibodies can mediate 
pathogenesis of a second DENV infection in vitro, but in vivo 
corroboration has not been possible because no animal model of 
antibody-enhanced dengue disease is currently available.
Ms. Williams then described a mouse-adapted DENV2 strain, 
DS10, that produces a tumor necrosis factor (TNF)-dependent 
fatal vascular permeability syndrome in interferon-α/β and 
γ-receptor-deficient (AG129) mice 4–5 days after intravenous 
infection.8 The AG129 mouse model is permissive to infection 
with all four DENV serotypes, displays relevant tissue and cel-
lular tropism, produces long-lasting serotype-specific and sero-
type-cross-reactive anti-DENV antibodies of a balanced isotope 
ratio, and generates a vascular leakage syndrome that is similar to 
human dengue disease. Ms. Williams confirmed the critical role 
of FcγR interaction in ADE in vivo. Using the F(ab)’2 fragment 
of 4G2 and the N297Q variant of hE60-IgG1, it was verified 
that interaction of the anti-DENV mAb with the FcγR, and not 
binding of C1q, is essential for ADE in vivo. Ms. Williams also 
remarked that mAbs engineered to prevent FcγR interaction also 
exhibit prophylactic and therapeutic efficacy against DENV, and 
thus have potential as an antiviral strategy.
The molecular interaction of protective mAbs and the DENV 
envelope protein was the final topic of the presentation. Binding 
sites were mapped to epitopes in regions in domain I (lateral ridge), 
domain II (dimer interface, lateral ridge and fusion loop) and 
domain III (lateral ridge, C-C’ loop and A strand). The anti-C-C’ 
loop and anti-domain I/II dimer interface mAbs are prophylactic 
against an ADE infection, but neither are therapeutic as wild-type 
or as a non-FcγR binding variant.9 Ms. Williams concluded with 
an outline of future work that involved further characterization of 
mouse and human mAb determinants of protection and enhance-
ment at the serotype domain and epitope specificity level.
Ronald Vogels (Crucell) first emphasized the importance of 
his company’s motto: “Combating infectious diseases by bring-
ing innovation to global health.” He commented on the difficulty 
of treating influenza A and how bNAbs against influenza can 
help. An important option for the prevention and treatment of 
influenza is the administration of purified or recombinant anti-
bodies for groups 1 and 2 influenza A viruses. Dr. Vogels noted 
that influenza hemagglutinin (HA) is an antigenic glycoprotein 
found on the surface of the influenza viruses and is the main anti-
genic determinant; neutralizing antibodies can affect HA bind-
ing to the cell receptor and subsequent fusion.
In 2008, Crucell discovered CR6261,10 a mAb that is able to 
prevent and cure influenza by binding to a highly conserved epi-
tope in the HA stem with heavy chain only.11 Dr. Vogel high-
lighted that CR6261 is able to neutralize a broad range of group 1 
influenza viruses, including the currently circulating H1N1 sea-
sonal influenza strains and the highly pathogenic H5N1 (‘bird 
flu’) virus. However, group 2 HAs such as H3, H7 and H10 
strains are not recognized by CR6261 because they have a glycan 
structure in the hydrophobic pocket that prevents recognition by 
the VH1-69 germline gene of CR6261.
Dr. Vogel then described the isolation of two new mAbs, CR8020 
and CR8043, that neutralize multiple phylogenetically distinct H3 
strains and H7 and H10 subtypes. Prophylactic administration of 136  mAbs  Volume 3 Issue 2
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Jean-Luc Teillaud
The second day of the conferences was divided into two paral-
lel tracks, Antibody Engineering and Antibody Therapeutics, 
with morning and afternoon sessions for each track. Topics in 
the Antibody Engineering tracks included antibody biosynthesis, 
structure and stability and antibodies in a complex environment, 
while topics in the Antibody Therapeutics track included pre-
clinical and early stage development of antibody therapeutics and 
clinical updates of antibody therapeutics.
Antibody Engineering:  
Antibody Biosynthesis, Structure and Stability
The morning session of the Antibody Engineering track, chaired 
by Andreas Plückthun (University of Zürich), was dedicated to 
discussion of the glyco-engineering of IgG and the structural 
changes and characteristics that may facilitate the folding and 
the production of IgG in yeast and bacterial cells.
The selection of aglycosylated full-length IgG from reper-
toires displayed on E. coli was presented by George Georgiou 
(University of Texas at Austin). Produced in the periplasm, 
these IgG are captured by an Fc binding protein expressed at the 
inner membrane of the bacteria. Permeabilization of the outer 
membrane makes it possible to screen for fluorochrome-labeled 
ligands. Multiple rounds of fluorescence-activated cell sorting 
(FACS) allow the selection of antibodies with affinity in the 
nanomolar range.1 Antibodies against the protective antigen of 
Richard Lerner (The Scripps Research Institute) discussed 
the capabilities and power of combinatorial antibody libraries, 
which lies within the chemistry of large numbers. To illustrate 
his point, Dr. Lerner discussed the insights gained from an anti-
body library constructed from cells taken from Turkish chil-
dren infected with avian influenza using phage display.13 The 
isolated antibodies, which use the VH1-69 family and have a 
low number of somatic mutations while displaying no similar-
ity between CDR3 loops, bind to the conserved stem of HA. 
These libraries revealed unprecedented antibodies and offer 
hope for universal neutralization. Dr. Lerner then discussed 
using large combinatorial antibody libraries as a representation 
of the immunological repertoire in health and during disease. 
Researchers developed combinatorial libraries from patients 
suffering from chronic rejection of transplanted human kidneys 
in order to understand how B-cell infiltrates (lymphoid clus-
ters) are important to the survival of the kidney. By comparing 
clones from donors of successful and rejected transplants, it was 
learned that the lymphocytes did not originate in the host, may 
be lymphoma-like, and that they may be escape mutants from 
T-cell regulation.
Sir Gregory Winter (Medical Research Council) discussed the 
use of chemistry to tailor phage repertoires for drug development. 
He recapitulated the importance of phage display by discussing 
the advances made with human therapeutic antibodies. He com-
pared and contrasted antibodies with chemical drugs with regard 
to properties such as target affinity and specificity, and targeting 
of intracellular antigens. He then discussed single domain anti-
bodies (dAbs). Elimination of one of the partner domains from 
an Fv allows dAbs to recognize its cognate antigen with lower 
affinity than parental mAb, but the absence of immunoglobulin 
constant domains removes the natural effector functions of dAbs, 
thereby making it necessary to equip them with an engineered Fc. 
Sir Gregory Winter’s final topic was phage-encoded combinato-
rial chemical libraries based on bicyclic peptides.14 Basically, novel 
accessory effector moieties are made using synthetic repertoires, 
encoding Cys-NX-Cys-NX-Cys (where x is a random amino acid 
and n = 0–8 amino acids), to mimic the rapid chemical reaction 
of trimethylbenzene. He concluded by describing two successful 
examples, PK15 and uPA in tumor invasion.
The session ended with a “fireside” chat (made possible by a 
televised fire) with the pioneers of phage display. The panel com-
prised Richard Lerner (The Scripps Research Institute), John 
McCafferty (Cambridge University), George Smith (University 
of Missouri), Sir Gregory Winter (Medical Research Council), 
Andrew Bradbury (Los Alamos National Laboratories), and 
James Marks (University of California, San Francisco). The 
open format elicited questions and comments on topics ranging 
from the quality of reagents to opinions about the utility of the 
technology.
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Bacillus anthracis have been isolated. Aglycosylated IgGs binding 
to activating Fcg receptors (FcγRI, FcγRIIa and FcγRIII) but 
not to inhibitory FcγRIIb were also generated. These IgG have 
potent anti-tumor killing activities in vitro and in vivo due to 
their lack of engagement of the inhibitory receptors, thus favor-
ing the activities of activating FcγRs.
Marc d’Anjou (GlycoFi/Merck & Co.,) discussed the control 
of post-translational modifications of recombinant proteins in 
humanized Pichia pastoris yeast. The capacity to engineer and 
to produce (with an excellent fidelity during the scaling-up of 
the process and from batch to batch) large amounts (>2 g/L) 
of proteins, notably antibodies, with pre-determined human 
N-glycan structures that impact the solubility, serum half-life 
and effector functions of antibodies paves the way to a new para-
digm for the development of therapeutic proteins.2,3 Therapeutic 
antibodies produced in humanized P. pastoris exhibit pharmaco-
kinetic (PK) properties similar to the same antibodies produced 
in mammalian cells (e.g., CHO). Moreover, the in vivo activ-
ity of a neutralizing anti-virus antibody produced in humanized 
P. pastoris appeared to have a similar potency in viral infec-
tion prophylaxis as the same antibody produced in mouse NS0 
cells. Also, an anti-CD20 antibody produced in humanized   
P. pastoris, devoid of fucose, was capable of depleting B cells 
in the presence of cells from an IgG1 low-binder F/F FcγRIII 
(CD16) donor, whereas there was no response to rituximab 
in the same assay.4 This technology allows the generation of 
100% afucosylated highly cytotoxic antibodies. Another inter-
esting use of the humanized P. pastoris is the alteration of the 
N-glycosylation often present in the CDRs and framework 
regions of antibodies. It can lead to severe adverse events such 
as hypersensitivity, as observed with cetuximab which exhib-
its an N-glycan in its CDR-H2 when produced in SP2/0 cells.   
The humanized P. pastoris offers an alternative by fine-tuning 
the glycosylation profile of such antibodies.
Antibody Engineering:  
Antibodies in a Complex Environment
The first part of the afternoon session of the Antibody Engineering 
track, chaired by Richard Begent (University College London) 
focused on the long-term effects of antibody treatment on the 
immune system of the host, on the T-and B-cell immunogenicity 
of polyvalent vaccines made of mosaic proteins and on the role of 
affinity in the anti-tumor efficacy of antibodies.
Jean-Luc Teillaud (INSERM) showed that the treatment 
of tumor-bearing immuno-competent mice with an anti-
CD20 mAb induces a long-lasting adaptive cellular anti-tumor 
response through the early recruitment of CD4+ cells.5 When 
the CD4+ compartment is depleted before tumor engraft-
ment and antibody treatment, mice are no longer protected 
and die rapidly. This long lasting effect, which requires the 
presence of an intact Fc portion, is a “vaccine-type” effect, as 
evidenced when mice are challenged with tumor cells several 
months later. The presence of T cells protects these mice from 
the tumor challenge, whereas the depletion of CD4+ cells just 
before tumor challenge or the lack of CD8+ cells (using CD8 
knockout mice) abolish the protection. Thus, this in vivo model 
demonstrates that, besides inducing early events such as killing 
or phagocytosis of tumor cells, antibody treatment can elicit 
a cellular adaptive memory immune response that ensures a 
long-term anti-tumor protection. Injection of IL-2 after tumor 
challenge reinforces the anti-tumor protection whereas it has 
no potentiating effect at the initiation of the antibody treat-
ment. Moreover, the mouse anti-CD20 mAb used in this study 
has been chimerized and a low-fucose antibody selected by LFB 
S.A.6 This low-fucose chimeric antibody (LFB-R603) is cur-
rently undergoing evaluation in a Phase 2 study in patients with 
B chronic lymphocytic leukemia (B-CLL).
The design of mosaic proteins to achieve adequate T- and 
B-cell responses was then discussed by Bette Korber (Los Alamos 
National Laboratory). The initial model system is the HIV Env 
protein that exhibits extraordinary variability since up to 35% 
of amino acids can differ between two Env proteins and up to 
~10% amino acid variation can be observed in a single patient 
over time. Thus, any anti-HIV vaccination strategy has to deal 
with two problems related to patient-to-patient variability: (1) 
the variability of the T-cell receptor (TCR) and (2) the polymor-
phism of the HLA molecules. Both molecules should adapt the 
enormous variability of the HIV-derived peptides in order to be 
able to present them to specific T cells. It is a major challenge as 
T-cell responses have limited cross reactivity.
Dr. Korber explained that, using computational modeling, 
mosaic proteins have been designed to optimize the coverage 
of T-cell epitopes, while keeping common epitope variants in a 
natural protein context.7 Notably, a database map (termed LANL 
database) has made it possible to determine the CD8+ and CD4+ 
T-cell responses to p24 (positions 100–200). HIV evolution 
has been mimicked by in silico recombination using a genetic 
algorithm to optimize vaccine epitope coverage. Mosaic HIV-1 
vaccines containing mosaic HIV-1 Gag, Pol and Env antigens 
have been shown to expand the breadth and the depth of cel-
lular immune responses in rhesus macaques without compromis-
ing its magnitude.8 They elicit CD8+ T lymphocyte responses 
that confer enhanced immune coverage of diverse HIV strains in 
monkeys.9 Of note, the setting of “B-cell” mosaics is even more 
complex as antibodies “see” discontinuous regions in folded pro-
teins. However, some specific rules to build B-cell mosaics can 
be envisioned: (1) B-cell mosaics may present the most common 
mutations that impact antibody binding; (2) Affinity matura-
tion in the presence of the most common variants might produce 
antibodies that could neutralize more broadly. However, whether 
B-cell mosaics represent useful vaccine molecules remains to be 
evaluated.
The relationship between the affinity and the efficacy of 
antibodies directed against solid tumors was then examined by 
Gregory Adams (Fox Chase Cancer Center). Using a set of single 
chain Fv (scFv) binding to the same epitope of HER2/Neu but 
with different affinities, it was demonstrated in the early 2000s 
that an increase of affinity above 10-9 M was not beneficial to 
tumor uptake. The lowest affinity molecules exhibited diffuse 
tumor staining whereas scFvs with a Kd around 10-11 M showed 
only a perivascular staining.10138  mAbs  Volume 3 Issue 2
PK, but has numerous potential prospects in the areas of RNA 
therapy, viral genome therapy, intrabody delivery and vaccine 
delivery.
Antibody Therapeutics:  
Preclinical and Early Stage Development
The morning session of the Antibody Therapeutics track was 
chaired by Rathin Das (Synergys Biotherapeutics). As an intro-
duction, Dr. Das briefly reviewed relevant facts pertaining to 
the development of mAb therapeutics, e.g., global revenue was 
$40 billion in 2009, at least five $250 million–$2.1 billion deals 
involving antibody therapeutics have been done in the past year, 
human antibodies comprised 45% of the antibody pipeline in 
the 2000s and their approval success rate to date is 17.5%17 and 
discussed the promise shown by new product formats such as 
antibody-drug conjugates, bispecifics and biobetters.
Daniel Lightwood (UCB-Celltech) described the develop-
ment and characterization of a potent inhaled anti-IL-13 Fab for 
treatment of severe asthma. IL-13 is implicated in the pathogen-
esis of asthma through a variety of means, e.g., recruitment and 
activation of eosinophils, activation of chemokine and cytokine 
expression in the vascular endothelium. UCB-Celltech’s strategy 
is to deliver a high-affinity neutralizing Fab using a nebulizer 
in the preclinical and early clinical studies, and follow with a 
dry powder formulation. The inhaled delivery has advantages 
because the drug can be delivered directly to the site of action 
with very limited systemic exposure, which allows the drug also 
to be quickly withdrawn.
IL-13 neutralizing antibodies were initially selected from can-
didates generated from the antibody discovery platform UCB 
selected lymphocyte antibody method (SLAM), which is a way 
to obtain heavy and light chain variable region gene sequences 
directly from single specific B cells. SLAM involves four steps: 
(1) culture of immune B cells; (2) primary screening; (3) con-
solidation of positives and secondary screening; and (4) V-region 
gene isolation. The IL-13 screening cascade included a homog-
enous bead-based assay that was used to identify hIL-13 binders, 
a STAT-6 secreted alkaline phosphatase reporter assay to iden-
tify IL-13 functional antagonists and a Biacore A100 analysis to 
estimate affinity and determine mechanism of neutralization. 
Starting with ~109 B cells, 7,500 positives from the primary bind-
ing assay were reduced to 100 VH-VL gene pairs that yielded 27 
unique families of recombinant antibodies. A total of five unique 
antibodies met the selection criteria for continued development. 
Six CA652γ1 Fab grafts were evaluated for affinity, Tm, stress-
induced aggregation and pH-induced unfolding. Significant 
variability in stability profiles were observed between humanized 
grafts despite only minor differences in amino acid sequence. 
The candidate selected for preclinical evaluation, CDP7766, 
demonstrated activity in a cynomolgus macaque model of allergic 
asthma when delivered via inhalation.
David Valacer (Tolerx, Inc.) discussed the preclinical devel-
opment of TRX518, an aglycosylated, humanized IgG1κ mAb 
that is currently in a Phase 1 study (NCT01239134) in adults 
with biopsy-proven unresectable Stage III or Stage IV melanoma. 
Dr. Adams noted that recent experiments have demonstrated 
that high affinity anti-HER2/Neu scFv rapidly internalize into 
tumor cells and are degraded within the cells.11 Thus, the balance 
between the IgG off-rate (making the antibody available again 
for further binding to tumor cells) and IgG internalization (fol-
lowed by the degradation of the antibody) is in favor of the inter-
nalization/degradation pathway when high affinity antibodies 
are used. This leads to the rapid catabolism of high affinity anti-
bodies in vivo, resulting in limited tumor penetration. In fact, 
use of high or intermediate affinity antibodies could also depend 
on the stage of tumor development at the time of the treatment. 
Experiments using a set of anti-human epidermal growth fac-
tor receptor (EGFR) IgG antibodies that cross-react with mouse 
EGFR are ongoing in a mouse model to better delineate the opti-
mal time points for use of either high- or intermediate affinity 
antibodies.
A new gene-silencing technology mediated by antibodies was 
presented by Yong-Sung Kim (Ajou University). Professor Kim 
described “interfering transbodies” as cell-penetrating antibodies 
equipped with sequence-specific nucleic-acid-hydrolyzing activ-
ity that penetrate into the cytosol of living cells and preferen-
tially recognize and hydrolyze a target mRNA, which leads to 
target gene silencing. His group is conducting studies with 3D8,   
a DNA/RNA hydrolyzing antibody isolated from an auto-
immune MRL-Ipr/Ipr mouse using hybridoma techniques.12 
ScFv, VL single domain and VH single domain derivatives of 
3D8 have been generated and humanized.13,14 When incubated 
with HeLa cells, 3D8 scFv was shown to penetrate into cells 
via caveolae-mediated endocytosis and localize in the cytosol 
in a concentration (range of 1–20 μM) and time-dependent   
(range of 0.5–48 h) manner.15 When incubated with HeLa cells 
for 2 h at a concentration of 10 μM, the 3D8 VL penetrated into 
the cells and localized to the cytosol without further trafficking 
into the nucleus.
Professor Kim described experiments to generate variants of 
3D8 VL with improved properties. Variants were selected from a 
synthetic library of 3D8 VL randomized residues located in one 
of two beta-sheets by screening for target-specific binding using 
immunomagnetic cell sorting (MACS) and FACS. 3D8 VL vari-
ants that had 100–1,000-fold higher affinity and 2–5-fold greater 
selective hydrolyzing activity for target substrates than for off tar-
gets were isolated.16 In one example, sorting was against the 18-bp 
ssDNA HER218 substrate corresponding to gene nucleotides 
2,391–2,408 of the Her2/neu gene. Selected mutants showed 
preferential DNA/RNA hydrolyzing activity for the target sub-
strate. Professor Kim noted that the HER218-selective 4MH2 
variant penetrated into cells and showed comparable downregu-
lation of HER2 expression to that of a small-interfering RNA 
targeting the same HER2 sequence, resulting in apoptotic cell 
death of HER2-overexpressing breast cancer cells.
Results from Professor Kim’s laboratory thus suggest that 
interfering transbodies with cell-penetrating, sequence-selective 
and nucleic acid-hydrolyzing activities can induce target gene-
specific gene silencing. Professor Kim concluded by noting that 
the interfering transbody approach has challenges, including 
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antibody. The example illustrated use of Symphogen’s integrated 
screening platform, which allows the functional ranking of mix-
tures of mAbs for therapeutic use. A mixture of two anti-EGFR 
antibodies was selected among twenty mixtures, based on IC50, 
affinity, epitope-bin evaluation, and an in vivo tumor xenograft 
model. A 1:1 mixture of these two chimeric IgG1 antibodies, 
binding to non-overlapping epitopes, located within the domain 
III of EGFR, induced strong EGFR internalization and degra-
dation (as opposed to cetuximab), whether the EGFR exhibited 
mutations or not. Sym004, therefore, may be appropriate as a 
treatment for a broader patient population than the currently 
available anti-EGFR antibodies because it leads to the inhibi-
tion of all EGFR-related signaling events. The mixture showed 
superior efficacy in vivo in animal models as compared with 
cetuximab and panitumumab.21 This result is likely due to the 
combination of different inhibitory mechanisms, including 
receptor blockade, receptor internalization and degradation, as 
well as activation of the effector mechanisms ADCC and CDC, 
induced by the mixture of antibodies. A discussion with the US 
Food and Drug Administration about the way toxicity should be 
tested (mixture vs. individual antibody) is ongoing. Dr. Pedersen 
pointed out that whether the concept of targeting multiple epi-
topes on a single molecule can be extended to other tumor tar-
gets such as HER2/Neu is still a matter of debate. A Phase 1/2 
clinical study in cancer patients with refractory or recurrent solid 
tumors is ongoing and should bring interesting results regarding 
the safety and efficacy of the approach.
The renaissance of bispecific antibodies (BsAbs) in oncology 
was then discussed by Matthew Robinson (Fox Chase Cancer 
Center). Based on the important role of ErbB3 in the mecha-
nisms of ErbB2/EGFR resistance to targeting agents (due to 
the direct link of the ErbB3-dependent signaling with the 
PI3K/Akt pathway), a BsAb single chain Fv directed against 
ErbB2 (also known as HER2) and ErbB3 (MM111; Merrimack 
Pharmaceuticals) has been developed and evaluated in vitro 
and in vivo.22 It was hypothesized that the use of this BsAb 
would increase the selectivity of the targeting and would induce 
a strong anti-tumor effect. By fine-tuning the affinity/avidity 
of the BsAb through an anti-ErbB3 arm with a Kd of 1.6 x 10-7 
M and an anti-ErbB2 arm with a Kd in the nanomolar range, 
only tumors expressing both ErbB2 and ErbB3 are targeted as 
shown by 125I-BsAB biodistribution studies in tumor bearing 
SCID mice. This BsAb also mediates inhibition of tumor cell 
growth in vitro. It is currently undergoing evaluation in two 
Phase 1/2 studies (NCT00911898, NCT01097460) of HER2+ 
breast cancer patients.
Dr. Robinson then discussed the optimization of the use of 
BsAb (e.g., in combination with standard-of-care chemotherapeu-
tics and biologics) and the construction of next generation BsAb 
formats (e.g., antibody drug conjugates, new BsAbs). Notably, he 
stressed that certain epitopes targeted by anti-ErbB3 antibodies 
are important because the in vitro efficacy of these antibodies 
segregates with epitope. Thus, panels of scFv have been generated 
that target defined epitopes on Erb family members; they have 
been formatted as scFv BsAb to test the most promising pairs in 
terms of in vitro and in vivo anti-tumor effects.
TRX518 targets the glucocorticoid-induced tumor necrosis factor 
receptor (GITR), which is a 228 amino acid residue transmem-
brane protein that has no death domain but which can induce 
apoptosis by binding with the death domain-containing protein 
Siva. GITR is found on multiple cell types involved in the regula-
tion of tumor immunity, e.g., regulatory T cells, effector T cells, 
B cells, NK cells, activated dendritic cells. Modulation of GITR 
or its ligand thus may have many potential clinical applications.
Dr. Valacer then discussed the preclinical evaluation of three 
antibodies: an IgG2a rat anti-mouse GITR mAb (2F8), an IgG1 
chimeric anti-human GITR mAb (Ch-6C8) and TRX518. 2F8 
combination therapy was shown to reduce tumor growth and 
extend survival, e.g., in combination with either gemcitabine 
(80 mg/kg) or cyclophosphamide (150 mg/kg), 2F8 dosed at 
4 mg/kg was shown to reduce tumor burden by 50–80% in a 
CT26 colon carcinoma model. Dr. Valacer postulated that an 
anti-GITR mAb may affect many aspects of a specific anti-tumor 
immune response to tumor-associated antigens. Ch-6C8 admin-
istration to cynomolgus monkeys resulted in increased humoral 
and cellular immune responses. In proliferation assays, TRX518 
was shown to enhance proliferation of sub-optimally stimulated 
T cells, but it did not act as a superagonist. In a GLP toxicology 
study in non-human primates, the half-life of TRX518 dosed at 
5 or 50 mg/kg was 3.8 and 2.6 days, respectively. No cell subset 
depletion was observed and there was no increase in cytokine 
induction or auto-antibodies. The first-in-humans ascending 
dose study of TRX518 was initiated in November 2010 and the 
estimated primary completion date for the study is June 2012.
The therapeutic use of cytokine/anti-cytokine complexes 
to intensify the in vivo potency of cytokines was discussed by 
Charles Surh (The Scripps Research Institute). The combina-
tion of IL-2 with certain anti-IL-2 antibodies stimulates either 
memory effector T cells or regulatory cells (Treg) depending on 
the antibody used. Thus, the choice of the antibody present in 
the complex should be adapted to the pathology to be addressed. 
A prostate tumor mouse model showed that a particular complex 
could efficiently stimulate the low CD8+ anti-tumor response 
developed by the animals.18 Conversely, the use of another anti-
IL-2 antibody in the anti-IL-2/IL-2 complex induced the expan-
sion of Treg and not that of effector cells, leading to resistance 
to experimental autoimmune encephalomyelitis, as well as a 
long-term acceptance of islet allografts.19 These differences are 
related to the ability of IL-2 present in the complexes to bind over 
longer periods of time either to the high affinity IL-2 receptor 
(comprising the α, β and γ chains), provoking the expansion 
of Treg, or to the low affinity IL-2R (comprising only β and γ 
chains), inducing CD8+ memory T cells. In addition, the use of 
FcRn-/- knockout mice abrogated the induction of these effects 
by anti-IL-2/IL-2 complexes, as well as the effect of IL-7/anti-
IL-7 complexes on T-cell development. Thus, the prolongation of 
the IL-2 half-life and the capacity of IL-2 to interact with CD25 
(the α chain of IL-2R) are critical parameters for achieving these 
effects.20
Mikkel Pedersen (Symphogen) detailed the synergistic 
anti-tumor effect obtained with SYM004, a mixture of anti-
EGFR antibodies, as compared to the use of a single anti-EGFR 140  mAbs  Volume 3 Issue 2
the most abundant strains of HIV. The mAb received FDA Fast 
Track designation.
Three studies of PRO140 have been completed. Two stud-
ies were designed as single dose, dose ranging (0.5–10 mg/kg) 
investigations of PRO140 in 30–40 patients,24,25 while the third 
study (NCT00642707) evaluated sc administration of PRO140 
at 162 mg or 324 mg dosed on days 1, 8 and 15 of the study.26 
PRO140 demonstrated potent, dose-dependent antiviral effects 
that were statistically significant, and the activity was observed 
for both iv and sc dosage forms. The virologic suppression was 
rapid and prolonged, and the increases in rates of antiviral 
response were dose-dependent, for both iv and sc dosage forms. 
Outgrowth of pre-existing CXCR4-using HIV-1 variants was 
observed in a small percentage (~7%) of subjects enrolled using 
a first-generation tropism assay, consistent with studies of other 
CCR5 co-receptor antagonists. No pre-existing R5 resistance 
to PRO140, i.e., resistance of the R5 HIV-1 strains to PRO140, 
has been observed, and no emergent R5 resistance was observed 
despite prolonged virologic suppression (up to six weeks) with 
monotherapy and slow elimination of drug.
Regarding tolerability, PRO140 was generally well-tolerated 
when administered via either i.v. or s.c. routes. There were no 
drug-related serious adverse events and no pattern of toxicity. The 
administration-site reactions were infrequent, mild, transient 
and self-resolving. Dr. Olson also mentioned that, to date, no 
dose-limiting toxicity has been seen in humans or in preclinical 
studies. The peak and overall exposure increased approximately 
in proportion with dose and the serum half-life was 3–4 days 
for both the iv and sc dosage forms. Regarding immunogenic-
ity, anti-PRO140 antibodies were detected infrequently, at low 
titer and without impact on PK or antiviral outcomes. Dr. Olson 
noted that the sc dosage route was selected for further devel-
opment based on its potent efficacy, favorable tolerability and 
potential for convenient self-administration by patients.
Lioudmila Tchistiakova (Pfizer) presented the development 
of two anti-IL-13 neutralizing mAbs. Both antibodies inhibit 
the binding of IL-13 to the (IL-4Rα/IL-13Rα1) heterodimeric 
receptor. However, one of the mAbs blocks only the binding of 
IL-13 to the IL-4Rα chain of the receptor, while the other blocks 
the binding to both the IL-13Rα1 chain of the receptor and to 
another IL-13 membrane receptor, IL-13Rα, that lacks canoni-
cal Jak/STAT signaling functions.27 Both antibodies demon-
strate comparable reduction of lung inflammation, serum titers 
of Ascaris-specific IgE and Ascaris-triggered basophil histamine 
release in cynomolgus monkeys.28 Interestingly, although these 
two humanized antibodies exhibit the same affinity for IL-13R, 
only the antibody blocking the binding of IL-13 to IL-4Rα 
attenuated early and late stages of asthmatic responses follow-
ing allergen challenge, to a similar degree as leukotriene antago-
nists, in two clinical Phase 2 studies where mild, atopic asthmatic 
patients were tested with either one of the two antibodies. Both 
antibodies had no effect on the level of total IgE in blood and had 
identical PKs. However, analysis of serum IL-13 levels showed an 
increase only after infusion of the antibody blocking the IL-13/
IL-13Rα2 interaction, suggesting a role of this receptor in the 
clearance of IL-13 in vivo.
Christian Klein (Roche GlycArt) presented a novel strategy to 
generate new bispecific IgG formats, i.e., the Heavy (H) chain/
Light (L) chain “cross-over.” BsAbs are of particular interest when 
one wants to simultaneously block two soluble factors that exhibit 
complementary and overlapping activity, e.g., such as the two pro-
angiogenic factors, vascular endothelial growth factor (VEGF) 
and angiopoietin (Ang)-2. The latter molecule is produced during 
inflammatory processes or when tumors are developing.
To investigate the possibilities, an anti-VEGF x anti-Ang-2 
BsAb was generated using a “cross-over” strategy. Dr. Klein 
explained that the approach is based on the formation of HL 
dimers in which the VH-CH1 of the H chain is exchanged with 
the full L chain of each of the two antibodies (or only the VH 
and the VL are exchanged between the H and L chains). The 
VH-CH1 is produced as a light chain and the VL-CL is fused to 
the hinge-CH2-CH3 domains of the heavy chain. Alternatively, 
the VH is fused to the CL and produced as a light chain, while 
the VL is fused to the heavy chain constant domains. The hinge 
region is modified to form an elbow allowing each of the VH-VL 
pairs to bind their specific targets without any steric hindrance 
by the other pair. The HL monomers derived from each antibody 
are then associated through their Fc region by the method of the 
“knobs-into-holes” engineering of CH3 domains proposed by 
Paul Carter in 1996.23
The “cross-over” strategy leads to the generation of different 
BsAbs formats. These formats exhibit the same affinity for VEGF 
and Ang-2 compared to their parental counterparts as shown by 
surface plasmon resonance (SPR) and bind simultaneously to both 
antigens. In vivo assays in a tumor graft model and in a VEGF-
induced cornea micro-pocket assay showed that the best format is 
the one comprising a VL domain fused to the heavy chain con-
stant domains and the VH domain fused to the CL and expressed 
as a light chain. Thus the “cross-over” strategy is a promising engi-
neering approach whereby antibodies are not heavily engineered, 
contain “knobs-into-holes” mutations and novel fusion points, 
but do not require artificial linkers or connectors.
Antibody Therapeutics:  
Clinical Updates of Antibody Therapeutics 1
The afternoon session of the Antibody Therapeutics track, 
chaired by Trudi Veldman (Abbott Laboratories), focused on 
updates for therapeutic antibodies that are undergoing evalua-
tion in clinical studies.
The Phase 2a studies of intravenous (iv) and subcutaneous (sc) 
dosage forms of PRO140 in HIV-infected subjects were discussed 
by William Olson (Progenics Pharmaceuticals, Inc.). Dr. Olson 
reminded delegates that only 25 drugs are approved as treatments 
for HIV infection and none of these are cures. Challenges associ-
ated with HIV treatment include drug resistance, drug interac-
tions, long-term morbidities, incomplete recovery of the immune 
system and the requirement for daily, lifelong adherence to treat-
ment. PRO140 is a humanized IgG4 mAb that blocks HIV from 
entering and infecting healthy immune cells. It targets CCR5, 
which is a chemokine receptor that mediates normal trafficking 
and activation of immune cells and acts as the portal of entry for www.landesbioscience.com mAbs  141
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Tony Shock (UCB-Celltech) discussed the use of an anti-
human CD22 IgG1 humanized antibody (epratuzumab, licensed 
from Immunomedics) in patients with moderate-to-severe sys-
temic lupus erythematosus (SLE). CD22 is a member of the 
SIGLEC family of proteins and is an inhibitory receptor pres-
ent on B cells that decreases B-cell activation without depleting 
the B-cell compartment. Epratuzumab stimulates CD22 inter-
nalization and decreases the expression of some adhesion mol-
ecules on B cells from SLE patients (CD62L and β7 integrin), 
while the expression of β1 integrin is increased; it cross-reacts 
with CD22 of non-human primates. Also, it enhances the spon-
taneous migration of B cells and the migration of CD27- B cells 
towards the chemokine CXCL12.29 Moreover, it induces a mod-
est ADCC in vitro when macrophages are cultured with primary 
B cells. In vitro, it does not inhibit the IgM and IgG production 
by human B cells stimulated with pokeweed mitogen (PKW), 
pansorbin, sCD40L or anti-IgM. Interestingly, it also does not 
affect the primary and secondary immune responses to specific 
antigens (keyhole limpet hemocyanin, KLH; tetanus toxoid, TT) 
in cynomolgus monkeys, although a modest decrease in periph-
eral B-cell number has been observed. This suggests that the use 
of epratuzumab in humans will not reduce the antibody response 
to specific pathogens. Epratuzumab has been tested in a Phase 2b 
study (EMBLEMTM) (n = 227 patients stratified by disease sever-
ity). It was well-tolerated, the incidence of serious adverse events 
and infusion reactions was similar to that of placebo, and it 
induced clinically meaningful improvements in SLE in patients, 
e.g., enhanced improvements at week 12.
Finally, Olaf Stüve (University of Texas Southwestern Medical 
Center) presented data on the immunologic and radiologic status 
of a cohort of patients fourteen months after cessation of natali-
zumab (Tysabri®) therapy. Natalizumab is a humanized antibody 
against VLA-4 marketed for treatment of patients with multiple 
sclerosis (MS). A Phase 2 study failed to demonstrate a difference 
between natalizumab treatment groups and the placebo group 
with regard to gadolinium-enhanced lesions on  magnetic reso-
nance imaging (MRI) 3 months after discontinuation of therapy. 
Clinical MS disease activity was thus evaluated in 23 patients 
with MS after discontinuation of natalizumab therapy over a 
14 month period.30 Surrogate disease markers on MRI, immu-
nologic parameters in peripheral blood and cerebro-spinal fluid 
(CSF), and safety were also evaluated. Adverse events were moni-
tored. The majority of the patients were found stable for clinical 
disease activity, neuro-imaging and immune responses. The ini-
tial change in the CD4/CD8 ratio and the decrease in lympho-
cyte cell numbers returned to normal when patients were assessed 
14 months after cessation of natalizumab therapy. Furthermore, 
no infectious complication (notably no progressive multifocal 
leukoencephalopathy),31 was observed. An important question to 
be addressed now is how to define the patients who should be 
treated continuously vs. those who should receive natalizumab 
only as an induction therapy.32142  mAbs  Volume 3 Issue 2
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Thierry Wurch and Janice M. Reichert
As was the case on Day 2, the third day of the conferences was 
divided into two parallel tracks, Antibody Engineering and 
Antibody Therapeutics, with morning and afternoon sessions for 
each track. Topics in the Antibody Engineering track included 
antibody half-life and targeted nanoparticle therapeutics, while 
topics in the Antibody Therapeutics track included clinical 
updates of antibody therapeutics and development of biosimilar 
and biobetter antibodies.
Antibody Engineering: Antibody Half-Life:  
The Long and the Short of It
The session was chaired by Dario Neri (ETH Zurich) and the key-
note lecture of the session was delivered by Sally Ward (University 
of Texas Southwestern Medical Center). She first provided a com-
prehensive overview of the functions and mode of action of FcRn 
and mAb recognition.1 This MHC class I type receptor transports 
immunoglobulin (Ig) G molecules within and across a diverse array 
of different cell types, allowing the maintenance of IgG levels and 
the delivery of antigen in the form of immune complexes to degra-
dative compartments within cells.1 FcRn-antibody interactions are 
pH-dependent (high affinity at pH 6.0 but low affinity at pH 7.4) 
and have been mapped essentially to histidine residues on IgGs;1 
this interaction is not dependent on Ig N-glycosylation. IgG with 
Fc regions engineered to bind with higher affinity and reduced pH 
dependence to FcRn potently inhibit FcRn-IgG interactions and 
induce a rapid decrease of IgG levels in mice. Such FcRn blockers, 
called ‘Abdegs’ (antibodies that enhance IgG degradation), may 
have uses in reducing IgG levels in antibody-mediated diseases, 
and in inducing the rapid clearance of IgG-toxin or IgG-drug com-
plexes.1 Professor Ward also presented a novel transgenic mouse 
model, in which this Fc receptor can be conditionally deleted.2 In 
combination with mice that express Cre recombinase under the 
control of the Tie2 promoter (Tie2-Cre), the effect of site-specific 
deletion of floxed FcRn in endothelial and hematopoietic cells on 
IgG persistence could be analyzed.2 The pharmacokinetics and 
steady-state levels of IgG in Tie2-Cre mice that are homozygous 
for the floxed FcRn allele reveal a complete loss of FcRn function 
in regulating the half-lives of wild-type IgG.2 Novel microscopic 
imaging techniques have been developed by Professor Ward and 
colleagues to monitor intracellular events on the recycling path-
way that leads from sorting endosomes to exocytosis at the plasma 
membrane.3 In this system multiple planes can be simultaneously 
imaged within the cell in conjunction with visualization of the 
plasma membrane plane by using total internal reflection fluores-
cence (TIRP) microscopy. Using this imaging technique, Professor 
Ward showed that FcRn is transferred from the limiting membrane 
of such endosomes to lysosomes, and is rapidly internalized into 
the lysosomal lumen.3 By contrast, lysosomal associated membrane 
protein-1 (LAMP-1) persists on the limiting membrane. Receptor 
transfer is mediated by tubular extensions from late endosomes to 
lysosomes, whereas full fusion is rarely observed. The persistence 
of FcRn on the late endosomal limiting membrane, together with 
selective transfer to lysosomes, allows this receptor to undergo 
recycling or degradation. Consequently, late endosomes have func-
tional plasticity, consistent with the presence of the Rab5 GTPase 
in discrete domains on these compartments.3
David Szymkowski (Xencor) summarized the improvements 
observed by the Xtend antibodies resulting from point muta-
tions in the Fc portion of antibodies to improve half-life. This 
is based on the Xencor proprietary XmAb® Fc domains with a 
wide range of immunological properties. Nearly 2,000 different 
Fc variants have been designed and tested on various Fc binding 
partners (FcgR, C1q, FcRn). Thus an appropriate XmAb Fc can 
be selected to improve nearly any antibody’s half-life. Xtend-Fc 
relates to mutations that enhanced binding to the receptor FcRn, 
which results in a 2- to 4-fold increase in in vivo half-life in pri-
mates; no loss of antibody stability or disruption of binding to 
FcyR or protein A has been observed. Validated half-life improve-
ments for several antibodies in primates and huFcRn transgenic 
mice were presented. For bevacizumab-Xtend, dosage of once 
every two months achieved the same therapeutic efficacy as dos-
age of bevacizumab every 1–3 weeks. An improved version of 
cetuximab was generated by humanizing the variable domain, 
removal of an N-glycosylation site present in the CDR-H3 of 
cetuximab, and by applying the Xtend technology, resulting in a 
large improvement of efficacy. Similar improvements were shown 
for Xtend-Fc derivatives (or biosuperiors) for adalimumab, abata-
cept, omalizumab, trastuzumab, tanezumab and rituximab.
Volker Schellenberger (Amunix) discussed the XTEN tech-
nology to prolong protein half-life. PEGylation of proteins and 
peptides is a classical way to extent their half-life. It has been vali-
dated clinically since several marketed products are based on this 
modification. Amunix developed a novel technology based on a 
polypeptide chain that mimics the properties of PEG. XTEN is 
864 AA long, and composed only of the 6 AA Gly, Glu, Ser, Thr, 
Ala, Pro. Similarly to PEG, XTEN confers long serum half-life 
in humans, it is non-immunogenic and homogeneous. XTEN is 
produced recombinantly by genetic fusion to the protein drug of 
interest without requiring an independent conjugation step dur-
ing manufacture. Due to XTEN’s extended structure, it provides 
a bulking effect similar to PEG, with associated improvements 
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an A543 SCID mouse xenograft model (survival model);4 signifi-
cant survival was achieved with the DMS7322 AlbudAb derivative. 
This candidate also showed good binding to human and cynomol-
gus serum albumins, and was used to design a long-acting version 
of the 40 AA long peptide, exendin-4, a GLP-1 receptor agonist 
used in the treatment of obesity and diabetes. Several fusion pro-
teins between exentin-4 and various AlbudAbs were constructed, 
produced and evaluated for their binding to albumin and potency 
to activate GLP-1R, with the best candidates being evaluated in 
relevant mice models. Overall, exendin-4 AlbudAbs were effective 
in pre-clinical models: they inhibited feeding for three days follow-
ing a single dose and gave significant weight loss in diet-induced 
obese (DIO) mice, and they showed activity in a db/db mouse 
model of type II diabetes.
Dario Neri (ETH Zurich) presented data on antibody engi-
neering to modulate PK by chemical modifications or gene fusions. 
The prototypical mAb used in these different studies is a scFv frag-
ment, directed against the ED-B domain of oncofetal fibronec-
tin, an isoform specifically associated with tumor vasculature and 
termed L19.5 This antibody fragment has been conjugated to many 
different payloads, and Professor Neri discussed some of these.
Example 1. This case-study dealt with an iodinated L19 
derivative currently developed by Bayer Schering Pharma. Three 
ED-B-derivatives of L19 were investigated:6 dimeric single-chain 
Fv, “small immunoprotein” (SIP), and whole IgG1. These L19 
derivatives were labeled with I-125 or with In-111 and evaluated 
in F9 (mouse embryonal teratocarcinoma cells) tumor bearing 
mice. The most favorable therapeutic index was found for I-131-
L19-SIP followed by I-131-L19-IgG1.6 The therapeutic index of 
all In-111-labeled derivatives was inferior. The best therapeutic 
efficacy was observed using I-131-L19-SIP, resulting in signifi-
cant tumor growth delay and prolonged survival after a single 
injection.6
Example 2. L19 scFv was fused to interleukin-2 (IL2) and 
showed potent and efficacious activity in several orthotopic mouse 
models. Professor Neri presented data from a completed Phase 
1/2 clinical study that evaluated the safety, tolerability, recom-
mended dose and early signs of activity of L19-IL2 in a total of 21 
patients with progressive solid tumors; the study was expanded to 
specifically include patients with metastatic renal cell carcinoma 
(mRCC).7 The recommended dose was defined to be 22.5 Mio 
IU IL2 equivalents.7 The pharmacokinetic parameters of L19-IL2 
were dose proportional over the tested range, with a terminal half-
life of 2–3 h. Toxicities were manageable and reversible with no 
treatment-related deaths.7 Stable disease was observed in 51% of 
patients overall and 83% of mRCC patients after two cycles.7
Example 3. This example involved the portable albumin 
binder (AlbuFluor). The site-specific chemical modification 
{2-(3-maleimidopropanamido)-6-[4-(4-iodophenyl)butan-
amido]hexanoate albumin-binding moiety} of a C-terminal 
cysteine residue in scFv antibody fragments was presented:8,9 a 
small organic molecule capable of high-affinity binding to serum 
albumin could substantially extend serum half-life in rodents.9 
The strategy was implemented using the scFv fragment F8, spe-
cific to the alternatively spliced ED-A domain of fibronectin, 
another tumor-associated antigen. The chemically modified 
the addition of XTEN to exenatide (Byetta®), a 39 amino acid 
peptide marketed by Amylin Inc., for diabetes treatment, is 
expected to lead to improvements: (1) because of much flatter 
PK profile, the dosing could be changed from twice a day to as 
little as once a month, (2) exenatide causes a high frequency of 
nausea and vomiting attributed to the rapid, sharp concentration 
changes, which should be decreased due to the much flatter PK 
profile of the XTEN product, (3) exenatide is made by a com-
plex synthetic chemical process, but the XTEN fusion product 
is produced as a recombinant protein and can be concentrated to 
more than 60 mg/ml, (4) exenatide causes an immune response 
in 60% of patients, whereas the XTEN fusion is expected to be 
less immunogenic.
A novel antibody format developed by UCB CellTech was 
presented by David Humphreys (UCB CellTech). They rea-
soned that antibody therapeutics should start from Fab mol-
ecules, as they are robust and more stable than their IgG parent. 
IgG unfolding transitions are lower than that of the Fab, with 
the antibody CH2 domain being the “soft spot” of IgG1 and 
IgG2. However, the major drawback for therapeutic use of Fab 
fragments is their short half-life. This can be modulated by 
PEGylation or by adding a domain for binding to human albu-
min. Dr. Humphries presented a Fab-Fv fragment that carries 
an albumin-binding domain in addition to the classical antigen 
binding site, created by adding the VL of an albumin-binding 
antibody to the C-terminus of the C-k domain, and its VH 
domain to the C-terminus of the CH1 domain of a recombinant 
Fab fragment. An additional cysteine bridge within this addi-
tional Fv domain was included in some constructs. Anti-albumin 
antibodies were generated in rabbits, two candidates (CA645 and 
CA648) were selected, which yielded nanomolar binding affini-
ties to human, rat and mouse serum albumin, and their VH/
VL domains were cloned into a Fab-Fv scaffold. These fusions 
showed a 20-fold lower clearance rate in mice as compared to the 
Fab; Fab-645 yielded a half-life of 62 h in mice, corresponding 
to about 1 week in human. In vivo efficacy of Fab-Fv was similar 
to Fab-PEG in a model of inhibition of human peripheral B lym-
phocytes engraftment in SCID mice. Improvement of the actual 
Fab-Fv format is ongoing with engineering of cysteines for inter-
domain disulfide bonds and design of alternative linkers (5–25 
AA) between the Fab and Fv domains.
By applying the domain antibody (dAb) technology developed 
by Domantis (acquired by GlaxoSmithKline in 2006), Oliver 
Schon (GlaxoSmithKline) demonstrated how an human albumin-
binding dAb could be applied to improve the half-life of peptides 
and proteins. AlbudAbs are albumin-binding dAbs: by binding to 
serum albumin, AlbudAbs decrease clearance of therapeutic drugs 
covalently linked to them.4 This allows for tighter control of drug 
concentration in patients over longer dosing intervals. The coding 
sequence of an antagonistic dAb was genetically fused to that of an 
AlbudAb to generate a fusion protein with monovalent engagement 
with target and with tunable affinity of both partners of the fusion. 
No Fc-mediated effects are expected for such a fusion molecule, 
e.g., ADCC, CDC. Several families of AlbudAbs against rat serum 
albumin were generated, with nanomolar binding affinities. They 
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uptake, confocal laser scanning microscopy (CLSM) and MRI. 
The presented data demonstrated that antibody-functionalized-
SPIONs bound specifically to CEA-expressing human tumor 
cells, generating selective image contrast on MRI.14 In addition, 
the cellular interaction of the antibody-functionalized-SPIONs 
was influenced by hydrodynamic size and surface coating.14
Theresa Allen (Center for Drug Research and Development) 
presented an overview on the use of nanoliposomes targeted via 
scFv and their use in cancer therapy. Targeted liposomal drugs 
represent the next step in the evolution of liposomal drug delivery 
in cancer treatment. In various preclinical cancer models, anti-
body-targeted PEGylated liposomal drugs have demonstrated 
superior therapeutic effects over their non-targeted counter-
parts.15 ScFv has gained popularity as a targeting agent of choice 
over other fragments or whole Ab. For clinical development, scFv 
are potentially preferred targeting agents for PEGylated liposomes 
over mAb and Fab’, owing to factors such as decreased immuno-
genicity and pharmacokinetics/biodistribution profiles that are 
similar to non-targeted PEGylated (Stealth) liposomes.15 In a first 
example, long-circulating (Stealth) immunoliposomes (SIL) that 
were targeted against the B-cell antigen CD19, via a whole HD37 
monoclonal antibody (HD37 mAb) were described.16 Compared 
to untargeted liposomes, SIL showed increased binding in vitro 
to CD19-expressing Raji cells and, when loaded with doxorubicin 
(SIL-DXR), increased cytotoxicity against Raji [CD19(+)], but 
not Molt4 [CD19(-)] cells. Pharmacokinetics and biodistribution 
studies showed that SIL-DXR targeted via HD37 Fab’ exhibited 
the same long circulation half-life as SL-DXR.16 All SIL-DXR 
extended the mean survival time of Raji-bearing mice compared 
to SL-DXR or free DXR. SIL-DXR targeted via HD37 Fab’ had 
the longest circulation half-life, and appeared to be slightly more 
effective in prolonging survival times than SIL-DXR targeted via 
either HD37-c-myc-Cys-His5 single chain Fv fragment or HD37 
mAb.16 In a second example, Her2-targeted SIL were described. 
In a murine breast cancer model, the rate and the extent of bio-
availability of doxorubicin entrapped in liposomes targeted by a 
single-chain antibody fragment against the HER2/neu antigen 
was compared to free DXR and non-targeted liposomal doxoru-
bicin (Doxil®). Breast cancer tumors contained the highest total 
levels of doxorubicin and the highest levels of bioavailable doxo-
rubicin when anti-HER2/neu-targeted liposomes were used, and 
the targeted liposomes also resulted in the greatest level of tumor 
control.17
James Paulson (The Scripps Research Institute) presented a 
novel way of targeting specifically B lymphoma cells using glycan 
ligands of CD22. CD22 is a member of the sialic acid-binding 
Ig-like lectin (SIGLEC) family that is known to be a regulator of 
B-cell signaling. Its B-cell-specific expression makes it an attrac-
tive target for immunotoxin-mediated B-cell depletion therapy 
for the treatment of B-cell lymphomas and autoimmune dis-
eases. CD22 is well described as an endocytic receptor and that, 
after internalization, it is targeted for degradation. In contrast, 
Professor Paulson and colleagues have demonstrated CD22 is 
instead constitutively recycled to the cell surface.18 The glycan 
ligand-based cargo attached to CD22 is released and accumu-
lates intracellularly as CD22 recycles between the cell surface 
scFv-F8 antibody fragment exhibited a dramatic increase in 
tumor uptake.8,9
Antibody Engineering:  
Targeted Nanoparticle Therapeutics
The session was chaired by James Huston (Boston Biomedical 
Research Institute), and the first lecture was given by John Park 
(University of California San Francisco Comprehensive Cancer 
Center), who discussed immunoliposomes (IL) in cancer treat-
ment. He first provided an overview of the current knowledge 
on nanoparticles/lipoparticles loaded with cytotoxic payloads, 
but without site-selective targeting. The most advanced com-
pound, nanoliposomal irinotecan (CPT-11) showed markedly 
superior efficacy when compared with free CPT-11 in human 
breast (BT474) and colon (HT29) cancer xenograft models.10 
Additional improvements in nanoparticle treatments should be 
achieved with the addition of molecular targeting, e.g., using 
liposomes linked to ligands such as monoclonal antibody frag-
ments directed against cancer-associated antigens. IL combine 
antibody-mediated tumor recognition with liposomal deliv-
ery and, when designed for target cell internalization, provide 
intracellular drug release.11 Recent advances in IL design include 
rapid selection of phage antibody-derived scFv for targeting, and 
methods for conjugation of ligands to existing approved liposo-
mal drugs such as PEGylated liposomal doxorubicin (Doxil®).   
A first example of an IL was presented as a novel anti-HER2 scFv 
F5 conjugated to Doxil®12 that is currently in development. It 
selectively binds to and is internalized by HER2-overexpressing 
tumor cells. This IL yielded increased efficacy in a variety of pre-
clinical mouse models including breast cancer (BT474, MCF7/
HER2, MDA453, B585) and other HER2-overexpressing can-
cers (CALU-3, N87).12 Liposome-antibody-targeting of long cir-
culating liposomes does not increase tumor localization, but does 
alter microdistribution and enables tumor cell internalization in 
vivo.12 The second example focused on an EGFR-targeted IL. 
Superior in vivo efficacy was established for glioma (U87, U87/
EGFRvIII), breast carcinoma (MDA468), lung (NSCLC, A549), 
colorectal and drug-resistant cancers (MDA231R overexpressing 
MDR1). The last topic dealt with the identification/selection of 
novel scFv candidates with the primary goal of achieving inter-
nalization.13 Primary panning was performed on MDA-MB231 
cells (basal type) and counter-selection was applied versus lumi-
nal breast cancer cells (i.e., MDA-MB 453).
The next presentation by Kerry Chester (University College 
London) introduced a novel and original application of iron oxide 
nanoparticles for imaging and cancer therapy. Superparamagnetic 
iron oxide nanoparticles (SPIONs) can substantially improve 
the sensitivity of magnetic resonance imaging (MRI), therefore 
SPIONs could be used to target and image cancer cells if func-
tionalized with recombinant single chain Fv antibody fragments 
(scFv). This hypothesis was tested by generating antibody-func-
tionalized SPIONs using a scFv specific for carcinoembryonic 
antigen (CEA), an oncofetal cell surface protein. SPIONs of 
different hydrodynamic diameter and surface chemistry were 
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intrinsic activity. The particular hinge region provides structural 
flexibility to both variable and constant domains via Fab arm 
rotation and waving and Fc rotation and controls Fab-Fc pla-
nar folding. Numerous Cys residues are involved in interchain 
(H-H or H-L) bonds. These major structural features are directly 
associated with the primary amino-acid sequence of the hinge 
region and thus to the antibody isotype. Numerous mutants or 
chimeric hinge regions (by swapping portions from different Ig 
isotypes and especially human IgG1 and IgG3) have been con-
structed and evaluated for their effector functions. A clear impli-
cation of the lower hinge portion (part of the CH2 domain based 
on genetic criteria) in complement activation was demonstrated. 
Some mutants located in the middle hinge portion affected FcgR 
binding and ADCC. On the other hand, much less is publicly 
known on the role of the hinge region in antigen binding.
Dr. Wurch and colleagues constructed a large series of 
mutants in this hinge region that modulate the flexibility and 
rigidity of the Fab portion; mutations included insertion of 
additional cysteine residues and amino acid deletions (1 to 4). 
These modifications were associated with a strong impact on the 
intrinsic activity of the resulting antibody mutants towards the 
target antigen: both agonistic and antagonistic activities were 
strongly modulated, ranging from weak to strong partial agonist 
and weak to efficacious antagonist. Introduction of additional 
cysteine residues was in some cases associated with mispairing of 
heavy and light chains, as was already noted for wild-type human 
IgG2 mAbs.
Antibody Therapeutics:  
Clinical Updates of Antibody Therapeutics 2
The keynote address for the Wednesday morning session was 
given by Barbara Rellahan (Division of Monoclonal Antibodies, 
US Food and Drug Administration), who discussed new and 
emerging mAb and mAb-related products such as bispecific anti-
bodies, mAb fragments and alternative scaffold proteins. She 
noted that the objective of targeting two antigens can be achieved 
by either one bispecific mAb or a cocktail of two mAbs, and that 
FDA does not have a preference for development of one type of 
product over the other. FDA’s guidance for industry that discusses 
nonclinical safety evaluation of drug or biologic combinations 
does generally recommend testing of each new entity individu-
ally, but indicates that if mAb are to be marketed together only, 
it may be possible to conduct studies only on the combination.   
Dr. Rellahan explained that there are advantages to both types, 
e.g., bispecific mAbs may have simpler manufacturing processes, 
but cocktail products can be evaluated individually for activity 
and safety, and their ratio can be adjusted accordingly.
Dr. Rellahan noted that antibody fragments and scaffold 
proteins may have advantages, but the possible disadvantages 
of engineered binding proteins should not be overlooked, e.g., 
there may be less knowledge on the structure/function relation-
ship, there may be greater off-target effects because the level of 
specificity may not be the same as a mAb, and immunogenicity 
may increase due to novel amino acid sequences in the protein. 
She expanded on the topic of immunogenicity by first noting 
and endosomal compartments.18 Antibodies to CD22 do not 
accumulate but remain bound to CD22 and recycle to the cell 
surface. Thus, antibodies targeting CD22 glycan were developed 
in an IL approach using Doxil®. The targeted liposomes were 
actively bound and endocytosed by CD22 on B cells, and sig-
nificantly extended life in a xenograft model of human B-cell 
lymphoma.19 Moreover, they bound and killed malignant B cells 
from peripheral blood samples obtained from patients with hairy 
cell leukemia, marginal zone lymphoma and chronic lympho-
cytic leukemia.19 Siglec-1 or sialoadhesin may also be an interest-
ing target for IL therapy. It exhibits highly restricted expression 
on tissue and inflammatory macrophages and on activated 
monocytes. This target might have an impact in the treatment of 
inflammatory responses that promote rheumatoid arthritis and 
tumor metastasis.
The last presentation of this session was given by Subhash 
Chauhan (University of South Dakota), who presented novel 
strategies for sensitizing cancer cells, with applications in ovarian 
cancers. Polymer micelle nanotechnology aims to improve the 
therapeutic efficacy of anti-cancer drugs while minimizing their 
side effects, and it can be applied with a range of chemotherapeu-
tics. Different types of polymer micelle technology based nano-
therapies were presented, e.g., poly(lactic-co-glycolide) (PLGA); 
polymerosomes; acid cleavable, thermosensitive, pH sensitive and 
cross-linked micelles.20 An important feature of polymer micelle 
nanotechnology is the small size (10–100 nm) of particles, which 
improves circulation and enables superior accumulation of the 
therapeutic drugs at the tumor sites.20 One example developed 
is based on curcumin, a natural polyphenolic compound that 
has shown promising chemopreventive and chemotherapeutic 
activities in cancer.21 But curcumin showed poor bioavailabil-
ity and suboptimal pharmacokinetics that largely moderated 
its anti-cancer activity in pre-clinical and clinical models. Thus 
curcumin was encapsulated in PLGA nanoparticles, in the pres-
ence of poly(vinyl alcohol) and poly(L-lysine) stabilizers, using 
a nano-precipitation technique.21 These curcumin nano-formu-
lations were characterized for particle size, zeta potential, drug 
encapsulation, drug compatibility and drug release. Encapsulated 
curcumin existed in a highly dispersed state in the PLGA core 
of the nanoparticles and exhibited good solid-solid compatibil-
ity. An optimized curcumin nano-formulation (nano-CUR6) 
has demonstrated two- and six-fold increases in cellular uptake 
performed on A2780CP ovarian and metastatic MDA-MB-231 
breast cancer cells compared to free curcumin.21 In these cells, 
nano-CUR6 has shown an improved anti-cancer potential in cell 
proliferation and clonogenic assays compared to free curcumin. 
This effect was correlated with enhanced apoptosis induced by 
nano-CUR6.21 Next, conjugation of the nano-CUR6 formula-
tion to two antibodies targeting either transferrin or anti-TAG-72 
(CC49) was presented. Western-blot confirmed antibody conju-
gation and imaging data demonstrated improved tumor specific 
targeted delivery of nano-CUR6 anti-cancer drug.21
To relate nanoparticles with the more classical antibody thera-
peutics,  Thierry Wurch (Institut de Recherche Pierre Fabre, 
Centre d’Immunologie Pierre Fabre) presented novel data on 
the influence of the antibody hinge region and the control of its 146  mAbs  Volume 3 Issue 2
pharmacokinetics of ASG-5ME monotherapy in patients with 
advanced prostate cancer, and a dose escalation, Phase 1 study 
[NCT01166490] to evaluate the safety and tolerability of ASG-
5ME and to identify the maximum tolerated dose in patients with 
pathologically confirmed metastatic pancreatic adenocarcinoma.
The clinical proof-of-concept (POC) strategy applied to date 
for development of U3-1287 (AMG 888) was presented by Thore 
Hettmann (U3 Pharma GmbH/Daiichi-Sankyo). U3-1287 
(AMG 888) targets HER3, which is a key dimerization part-
ner for HER receptors. HER3 directly binds PI3K and induces 
PI3K/AKT signaling, and is implicated in resistance mecha-
nisms to anti-HER therapeutic agents.22 U3-1287 (AMG 888) 
is a human IgG1 derived from XenoMouse® technology with Kd 
in the range of 1–3 nM, cross-reactivity in cynomolgus, rat and 
mice, and a clean safety profile (no observed adverse effect level at 
200 mg/kg in monkey and rat). The mAb inhibits proximal and 
distal HER signaling and induces rapid internalization of HER3.
Dr. Hettmann explained that the strategy for development 
included identification of appropriate indications, identifica-
tion of therapeutic combinations to overcome acquired resis-
tance and identification of predictive and prognostic biomarkers. 
He then described key features of the first clinical study. The 
IND was filed in May 2008 and a dose-finding Phase 1 study 
[NCT00730470] to assess the safety and tolerability of U3-1287 
(AMG 888) in patients with advanced solid tumors was initi-
ated in September 2008. The study was composed of two parts:   
(1) dose escalation phase (15–21 patients) and (2) dose expansion 
phase with an adaptive design (30 patients, 15 with non-small 
cell lung cancer and 15 with other solid tumors as in Part 1).   
In the study, U3-1287 (AMG 888) appeared to be safe and well-
tolerated with an adverse event profile as expected in patients 
with advanced solid tumors. In part 1, 50% of patients had a best 
overall response of stable disease. The drug exhibited non-linear 
PK, presumably mediated by dual linear and nonlinear clearance 
pathways. After the first dose, at doses above 3 mg/kg, the Cmax 
and AUC increased in an approximately dose-proportional man-
ner. The maximum tolerated dose was 20 mg/kg in Part 1 of the 
study. No neutralizing anti-drug antibodies have been detected to 
date. Dr. Hettmann concluded by remarking that the combina-
tion of U3-1287 (AMG 888) and erlotinib is currently undergo-
ing evaluation in a Phase 1b/2 study (NCT01211483) of EGFR 
treatment naïve subjects with advanced non-small cell lung can-
cer who have progressed on at least one prior chemotherapy.
Lessons learned and questions remaining about development 
of human IgG1 antibodies targeting insulin-like growth factor 
1 receptor (IGF1-R) for treatment of sarcomas were discussed 
by Lee Helman (National Cancer Institute, National Institutes 
of Health). He first noted that IGF signaling provides a sur-
vival signal that contributes to tumor cell resistance to DNA-
damage induced cell death. This resistance is associated with 
mammalian target of rapamycin (mTOR) signaling and can be 
reversed with agents that block mTOR; conversely, mTOR acti-
vation of Akt can be reversed by IGF1-R blockade. Dr. Helman 
then reviewed preclinical studies with anti-IGF1-R antibodies 
that provided early evidence to suggest a beneficial combina-
tion of mTOR inhibition with IGF1-R inhibition. The effects 
that, while in general the immunogenicity of chimeric, human-
ized and human mAbs is less than that of murine versions, there 
is still substantial variation seen between individual candidates. 
For example, immunogenicity rates of 55.6, 100 and 80% have 
been observed for specific chimeric, humanized and human 
(phage display-derived) mAbs. Dr. Rellahan noted that the lack 
of a sensitive assay may have led to an under-estimation of mAb 
immunogenicity for many products, and of particular concern 
are assays that are sensitive to product interference. She suggested 
that sponsors should not underestimate the importance of under-
standing product immunogenicity and the consequences of it 
on safety and efficacy, and that, if feasible, measures should be 
taken to reduce product immunogenicity, e.g., “de-immunizing” 
products, minimizing protein aggregates/particulates. She also 
noted that sponsors should develop a sensitive anti-drug antibody 
(ADA) assay, i.e., one able to detect ADA at levels of product 
present in patient samples, as early in development as possible, 
and that the immune response should be characterized, e.g., 
neutralizing or not, region of mAb the ADA is directed against 
should be identified.
In her concluding remarks, Dr. Rellahan provided suggestions 
for how sponsors can facilitate the review of novel proteins, e.g., 
request interaction with FDA early in development; for pre-IND 
candidates, specifically request product quality reviewer or ask 
CMC questions if input is needed; clearly describe the product 
in the submission cover letter; take advantage of all opportuni-
ties to interact with the FDA to gain feedback on your proposed 
development pathway.
David Stover (Agensys/Astellas) provided an update on ASG-
5ME, which is an antibody-drug conjugate (ADC) that targets 
SLC44A4. The antigen is a novel cell surface transporter that 
is a putative 10 transmembrane protein (710 amino acids) with 
an anion exchanger motif. SLC44A4 is homologous to human 
choline transporter and is overexpressed in multiple solid tumors, 
e.g., prostate and pancreatic cancer. ASG-5ME comprises a 
human IgG2kappa mAb derived from the XenoMouse® tech-
nology that is conjugated to monomethyl auristatin E (MME; 
3.7 drugs/mAb) through a protease cleavable dipeptide (valine-
citrulline) linker. Its high affinity to SLC44A4 (0.4 nM) is simi-
lar to that of the naked AGS-5M2; the ADC cross reacts with 
cynomolgus monkey ortholog. Dr. Stover explained that, after 
ASG-5ME binds to cells, the ADC is internalized via endocytosis 
and the MME is released into the cell via enzymatic cleavage of 
the linker. The MME is then available to bind to tubulin, which 
causes cell cycle arrest at G2/M and leads to apoptosis.
Dr. Stover presented data showing ASG-5ME mediates cyto-
toxicity in vitro and potent anti-tumor activity in xenografts 
that express the antigen. The terminal half-life estimates for 
ASG-5ME were 13.3 days in mouse (estimated from 3 mg/kg 
single dose), 15.2 days in rat (estimated post multiple 3 mg/kg 
doses) and 8.4 (±0.79) days in monkey (estimated from 3 mg/kg   
single dose). Dr. Stover noted that the ADC had excellent PK 
properties that were not significantly different from the naked 
mAb. GLP toxicity studies in cynomolgus monkeys suggest that 
the limiting toxicity is non-specific. ASG-5ME is currently in a 
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counterpart. He presented data that indicated that Type II mAbs 
are superior to Type I mAbs in depleting B cells,27 and that com-
plement was not important, but FcγR are critical for both Type I 
and II mAbs.28 He then presented experimental results for Type I 
anti-CD20 mAbs that indicated these mAbs internalize into cells 
and become degraded along with CD20 in an energy and tem-
perature dependent process. Specifically, after internalization, 
the Type I mAbs traffic to the early endosome and lysosomal 
degradation follows. Modulation of CD20 by the Type I mAbs 
ultimately leads to reduced phagocytosis of tumor cells as well as 
consumption from the sera.28
He then presented data indicating that the modulation rate 
of CD20 from the surface of different NHL sub-types might 
be linked to the efficacy of rituximab in the clinic, with those 
sub-types modulating rapidly doing less well clinically. Finally, 
Professor Cragg, presented data indicating that the inhibitory 
FcγRIIB is a key component of this process, precipitating the 
internalisation of rituximab in a cis-fashion from the surface 
of the same cell. He showed that Type II mAbs do not engage 
FcγRIIB and so are not regulated by this process. Professor 
Cragg concluded by stating that Type II mAbs have better thera-
peutic potential compared with Type I versions because they do 
not modulate and are therefore not consumed or removed from 
the cell surface.
A comparison of the EGFR antibodies zalutumumab (HuMax-
EGFR, Genmab), cetuximab (Erbitux®, Merck KGaA), panitu-
mumab (Vectibix®, Amgen) and nimotuzumab (Biomab-EGFR/
TheraCIM/Theraloc, Biocon/YM Biosciences/Oncosciences) 
was presented by Paul Parren (Genmab).
He first described the characteristics of the EGF receptor 
(EGFR), which is a 170 kDa Type I glycoprotein. EGFR is a 
tyrosine kinase growth factor receptor that binds EGF, as well 
several other EGF-like ligands. Signaling by EGFR plays a role 
in cell proliferation, differentiation and migration of normal cells 
and the receptor is frequently overexpressed in many tumors 
and associated with poor prognosis. Dr. Parren briefly reviewed 
format and the most advanced phase for the four EGFR anti-
bodies: (1) zalutumumab is a human IgG1 in Phase 3 studies 
of patients with head and neck cancer; (2) cetuximab is a chi-
meric IgG1 marketed as a treatment for head and neck cancer, 
and colorectal cancer; (3) panitumumab is a human IgG2 mar-
keted as a treatment for colorectal cancer; and (4) nimotuzumab 
is a humanized IgG1 marketed for head and neck cancer, and 
glioma, although it was not marketed in the US, Europe or Japan 
as of December 2010. All four antibodies bind a closely related, 
overlapping epitope on EGFR domain III. Only zalutumumab 
and nimotuzumab bind non-overlapping epitopes and are able to 
bind simultaneously to EGFR.
Dr. Parren provided specific details for zalutumumab, which 
was generated in a transgenic mouse (HuMAb-MouseTM), and 
selected for high affinity binding to human EGFR and effec-
tive inhibition of ligand binding (EC50 = 0.25 nM by ELISA).   
In terms of its in vitro concentration-effect relationships, inhibi-
tion of signaling by zalutumumab is most effective at saturating 
concentrations, induction of ADCC already at low concentra-
tions, and overall, target saturation ensures maximum efficacy. 
of IGF1-R inhibition were found to correlate with IGF1-R,   
i.e., low levels were a negative predictor. In addition, the effect 
of IGF1-R blockade on the decrease in pAkt was lost in long-
term xenografts,23 and this tachyphylaxis was abrogated with 
mTOR inhibition, leading to the question: What is the mecha-
nism of tumor regrowth?
Top-level results of a Phase 2 study (NCT00642941) of the 
anti-IGF1-R human R1507 mAb administered to patients with 
recurrent or refractory Ewing’s sarcoma (ES), osteosarcoma, 
synovial sarcoma, rhabdomyosarcoma (RMS) and other sarco-
mas were presented by Dr. Helman. The study is ongoing but 
not recruiting patients as of December 2010. The overall objec-
tive response rate for 115 eligible patients with refractory ES 
who were administered R1507 was 16.5% (11 durable, 8 short-
lived). Toxicities observed included thrombocytopenia (7%), 
anemia (7%), pain (7%) and hyperglycemia (3%). Dr. Helman 
noted that response did not correlate with IGF1-R, IGF1, IGF2, 
IGF2-R, IGF binding proteins-2, 3, 4, insulin receptor A or insu-
lin receptor B as assessed by quantitative real time polymerase 
chain reaction. The analysis of responders and non-responders 
for circulating nucleic acids, methylation patterns, RNA expres-
sion profiles and targeted sequencing is ongoing. Dr. Helman 
discussed the need to identify mechanisms of early response and 
then tumor re-growth and find ways to combine R1507 with other 
targeted therapies or chemotherapy. He concluded with remarks 
on a recent study by Huang et al. that defined and compared 
acquired resistance mechanisms for IGF-IR-targeted therapies.24
Antibody Therapeutics:  
Development of Biosimilar and Biobetter Antibodies
Mark Cragg (Southampton University) discussed CD20 as a tar-
get and why Type II anti-CD20 mAbs might make better thera-
peutics than Type I versions. Professor Cragg started by posing 
several critical questions: Are all anti-CD20 mAb equal? What 
are the critical effector mechanisms? What regulates the sensitiv-
ity of different diseases to anti-CD20? He then explained the 
differences between Type I mAbs, which include the marketed 
products rituximab, ofatumumab, as well as mAbs LT20, 1F5 
and AT80, and Type II mAbs such as tositumomab, FGM1 
and GA101. Type I mAbs induce TX-100 insolubility, i.e., 
CD20 translocation into TX-100 rafts and activate complement 
extremely efficiently, while Type II mAbs induce homotypic 
adhesion and cell death.25-27
Professor Cragg noted that Type I mAbs display good CDC, 
limited PCD and good ADCC, while Type II mAbs display 
poor CDC, good PCD and good ADCC. However, in vivo 
comparisons to determine which type is best are difficult due to 
differences in the human vs. mouse mAbs isotypes, e.g., in effec-
tor functions, half-life and potential generation of mouse anti-
human antibodies, and due to problems with xenografts, e.g., 
small numbers of cells, human-mouse reaction and protection of 
human cells from mouse complement.27
Professor Cragg discussed a preclinical huCD20 transgenic 
mouse model developed by Professor Mark Shlomchik at Yale 
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biologics now under review. According to PHSA section 351(i), 
BLAs are required for “a virus, therapeutic serum, toxin, anti-
toxin, blood or blood component or derivative, allergenic product 
or analogous product…applicable to the prevention, treatment 
or cure of a disease or condition of human beings.” The new leg-
islation amends this definition to include “protein (except any 
chemically synthesized polypeptide).”
The definitions of “biosimilar” and “interchangeable” bio-
similar products were provided by Ms. Konski. A biosimilar is 
highly similar to the reference product notwithstanding minor 
differences in clinically inactive components, with no clinically 
meaningful differences in terms of safety, purity and potency. An 
interchangeable biosimilar is a biological product that “may be 
substituted for the reference product without the intervention of 
the health care provider who prescribed the reference product.”
Ms. Konski then reviewed three basic elements for a US bio-
similar application: (1) analytical data showing the product is 
“highly similar” to a reference product despite “differences in 
clinically inactive components;” (2) animal studies, including 
the assessment of toxicity; (3) clinical study(ies) sufficient to 
demonstrate “safety, purity and potency in one or more appro-
priate conditions for use” that parallel an approved use of the 
reference product, although Ms. Konski noted that the FDA 
may determine that any of these three elements is not required 
in a given case. Other basic requirements are that the biosimi-
lar have the same mechanism of action as the reference product   
(if known) for the approved indication, the label for the biosimi-
lar must match the approved indication of the reference prod-
uct, the route of administration, dosage form and strength must 
match the reference product, and the product must be produced 
in an approved manufacturing facility.
Under the standard for approval, the FDA will approve the 
biosimilar application if the product is found to be “biosimilar” 
and it can be expected to produce the “same clinical result as the 
reference product in any given patient.” Ms. Konski noted that, 
under the standard for approval of an interchangeable biosimi-
lar product, FDA will label a biosimilar as interchangeable if it 
meets the standard for approval and, additionally, for a biological 
product that is administered more than once, the risk of safety or 
diminished efficacy of switching between the reference product 
and interchangeable is not greater than using the reference prod-
uct without the switch.
An important element of the legislation is the market exclu-
sivity period for the reference product, which was set at 12 years, 
i.e., no biosimilar product will be approved before the expira-
tion of the 12 year period. The market exclusivity period starts 
on the date of first approval of the reference product. There is 
also a four year data exclusivity period that starts on the date 
of first approval; no biosimilar application will be accepted by 
FDA during this period. Ms. Konski noted that innovators 
may obtain an additional six month pediatric exclusivity period 
based on similar provisions for small molecule drugs. The six 
month period is added to the four year filing period, i.e., no 
biosimilar application may be filed before 4.5 years have elapsed 
after first approval of the reference product, and to the 12 year 
data exclusivity period, i.e., no biosimilar application may be 
The dose-response relationship of zalutumumab treatment using 
different dosing schedules (10, 30 or 100 mg/kg on days 20 and 
34 or repeated dosing at 100 mg/kg) was studied in a subcutane-
ous A431 tumor xenograft model.29 Dr. Parren noted that a high 
dose level was required for full EGFR saturation. Effective eradi-
cation of established xenografts was observed with administra-
tion of zalutumumab on the repeated high dose schedule, and the 
in vivo effect was greater than expected from the in vitro results.
In comparing zalutumumab with cetuximab, panitumumab 
and nimotuzumab, Dr. Parren presented data that showed that 
these mAb differ in their efficacy to inhibit EGFR signaling and 
recruitment of effector cells for ADCC. In vitro, zalutumumab 
was significantly more potent in downmodulation of EGFR than 
the other mAb. Zalutumumab and cetuximab demonstrated 
comparable inhibition of A431 tumor cell growth and induction 
of ADCC and were in both assays significantly more potent than 
nimotuzumab and panitumumab. Specifically, panitumumab 
was as effective in recruiting ADCC by neutrophils and mono-
cytes, but less effective in NK cell-mediated ADCC, compared 
with zalutumumab.30 He noted that panitumumab-induced 
ADCC is mediated via FcγRIIa and affected by the functional 
FcγRIIa-R131H polymorphism, but IgG1 mAb are not affected. 
In established A431 xenograft models, tumor growth was inhib-
ited by 50 mg/kg i.p. doses of zalutumumab or cetuximab, but 
not by panitumumab and nimotuzumab administered at the 
same dose.
Finally, Dr. Parren presented data that combination treatment 
with a mixture of zalutumumab and nimotuzumab resulted in 
enhanced anti-tumor efficacy, being significantly more effec-
tive than the single agents or other EGFR mAb combinations. 
Solely the combination of the non-cross-blocking mAbs zalu-
tumumab and nimotuzumab resulted in enhanced anti-tumor 
efficacy, being additive for EGFR downmodulation and tumor 
cell growth inhibition, and synergistic for induction of CDC. 
In vivo evaluation of zalutumumab/nimotuzumab combination 
therapy revealed that combining these therapeutics significantly 
improved tumor growth reduction over single agent treatment, 
eradicating 8 of 10 tumors in a therapeutic A431 xenograft 
model. Interestingly, due to the selective binding characteristics 
of nimotuzumab the enhanced anti-tumor effects of the zalu-
tumumab/nimotuzumab combination seems preferentially tar-
geted to EGFR-overexpressing cells.
Antibody Therapeutics: Regulatory and Intellectual 
Property Issues for Biosimilar Antibodies
Antoinette Konski (Foley & Lardner LLP) reviewed the new US 
legislation on biosimilar products, which is officially titled the 
Biologics Price Competition & Innovation Act of 2009 (BPCI 
Act). The Act amended the Public Health Service Act (PHSA) 
to create a new pathway for the approval of biological products 
that are biosimilar to an approved reference product or biosimilar 
and interchangeable with an approved product; the Act became 
effective as of March 23, 2010 with full retroactivity. It applies to 
biologics already approved under the PHSA, i.e., any products for 
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“drug substance” was identical; if the same patient population, 
dosage and route of administration were included; and if the 
same mechanism of action was involved.
Mr. Shea then discussed the EMA’s draft guideline on simi-
lar biological medicinal products containing monoclonal anti-
bodies,31 which was released for consultation on November 18, 
2010. EMA will be accepting public comment on the guideline 
until May 31, 2011. Mr. Shea noted that the guideline states it 
is intended to complement earlier general guideline for demon-
strating biosimilarity of two products, and that “biobetters”, i.e., 
biologicals that are structurally or functionally altered in compar-
ison to already licensed reference products to gain an improved or 
different clinical performance, are specifically excluded. The bio-
similar antibody must not be inferior to the reference antibody. 
Regarding non-clinical studies, the guideline indicates a risk-
based approach to evaluate mAb products on a case-by-case basis 
will be taken. In vitro studies are to be conducted first, and these 
would be followed by a decision regarding what, if any, in vivo 
nonclinical studies are needed. According to Mr. Shea, the guide-
line states data from a number of comparative in vitro studies 
should be provided, and these should be designed to exclude all 
differences of importance in the concentration-activity relation-
ship. Regarding clinical studies, the guideline indicates that the 
most sensitive clinical model should be used in a homogeneous 
patient population, and the most sensitive patient population and 
clinical endpoint is preferred. When multiple therapeutic regi-
mens are licensed, the most sensitive key PK parameters should 
be assessed, but not all therapeutic dosage regimens need be 
tested. Clinical safety, including an assessment of immunogenic-
ity, must be demonstrated. In particular, immunogenicity must 
be carefully assessed when a different expression system is used to 
produce the antibody product. The guideline states that extrapo-
lation of clinical efficacy and safety data to other indications of 
reference mAb may be possible based on overall evidence of bio-
similarity, but extrapolation will be more challenging if the refer-
ence mAb is licensed as an immunomodulator and for cancer, 
which Mr. Shea noted is the case for rituximab. The final point 
was that the biosimilar applicant will need to propose pharmaco-
vigilance and risk management activities, which will be similar to 
those of the reference product but could be more.
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approved before 12.5 years have elapsed after first approval of 
the reference product.
Regarding the establishment of guidance documents for bio-
similars, Ms. Konski stated that the FDA may issue guidance, but it 
is not required. FDA must allow public comment on any guidance 
before issuing final guidance. If product class-specific guidance is 
issued, the FDA must include a description of the criteria they will 
use to determine whether a product is “highly similar” and the 
standards they will use to determine interchangeability. She also 
noted that FDA may indicate in guidance that “science and experi-
ence, as of the date of such guidance” will respect to a product or 
class does not allow approval of an application, but that FDA may 
subsequently modify or reverse such a guidance document.
Recent regulatory developments pertaining to biosimilar 
antibodies were reviewed by Timothy Shea (Sterne, Kessler, 
Goldstein & Fox P.L.L.C.). His main topics were the November 
2010 FDA public hearing on the BPCI Act and the European 
Medicine Agency’s draft guideline for biosimilar antibodies, 
which was issued in November 2010.
The FDA public hearing was held November 2–3, 2010 with 
the stated aim being “to receive information and comments from 
a broad group of stakeholders… regarding implementation of the 
BPCI Act”. A total of 40 speakers presented prepared statements 
to a panel of FDA experts and FDA accepted additional submis-
sions on the topic until December 31, 2010. Mr. Shea noted that 
most of the public comments focused on five issues: (1) clinical 
trials, (2) an interchangeability standard, (3) naming, (4) extrap-
olation and (5) foreign studies.
As described by Mr. Shea, the general consensus among pre-
senters at the hearing was that some clinical trials are needed, but 
they differed in the number and type of studies to be done. The 
major pharmaceutical firms generally favored larger and more 
sophisticated studies while the generics firms suggested fewer and 
more limited studies would be suitable. On the topic of an inter-
changeability standard, several patient advocacy groups and the 
Biotechnology Industry Organization (BIO) stated that this was 
not currently possible. Questions arose around whether the exact 
same clinical results would be necessary; would switching studies 
be needed?; would the same standards be applied as those applied 
when there were changes to innovator product?; is automatic 
substitution possible? On the topic of naming, discussion at the 
hearing included what nonproprietary name would be given to 
biosimilar/interchangeable product, with the Pharmaceutical 
Research and Manufacturing Association (PhRMA) biophar-
maceutical companies and patient advocacy groups arguing 
for a unique name and generic companies favoring use of the 
same nonproprietary name for the products. On the question of 
extrapolating data from clinical study for one approved indica-
tion to another, BIO indicated extrapolation may be appropri-
ate if the mechanism of action is well-understood, although a 
biopharmaceutical firm indicated that extrapolation between 
diverse indications such as rheumatoid arthritis and cancer was 
not feasible. A generics firm indicated that data from a single ran-
domized, controlled clinical study should be extrapolated to all 
indications. Regarding foreign, i.e., non-US, studies, questions 
arose regarding whether these studies would be acceptable if the 150  mAbs  Volume 3 Issue 2
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Renaissance of Bispecific Antibodies
The focus of the morning session was on bispecific antibodies. 
These types of molecules were invented 25 years ago, and there is 
now a resurgence of interest in their development as therapeutics.
Stanley R. Frankel (Micromet) reported on blinatumomab 
(MT103), a CD19/CD3-bispecific T-cell engaging (BiTE) con-
struct of two linked scFvs that strictly targets effector memory 
T cells to kill CD19 expressing malignant B cells. In preclini-
cal testing the antibody is potent in the pg/ml range, no T-cell 
receptor co-stimulation is required and low effector to target 
cell ratios are sufficient.1 A Phase 2 study of blinatumomab in 
relapsed acute lymphoblastic leukemia (ALL) showed a rapid and 
complete response in 80% of the patients. Minimal residual dis-
ease (MRD) was monitored with an elegant method determining 
the frequency of rearranged immunoglobulin and T-cell receptor 
genes with patient specific primers. Blinatumomab is also being 
tested in a dose-escalating Phase 1 study in non-Hodgkin lym-
phoma; a lower incidence of central nervous system events lead-
ing to discontinuation in patients with a high B:T-cell ratio has 
been observed.
Charlotte McDonaugh (Merrimack Pharmaceuticals) 
reported on the use of network models to identify key nodes 
within the ErbB network, and the creation of MM-111; a tri-
meric complex consisting of an anti-ErbB2 single chain Fv (scFv) 
and an anti-ErbB3 scFv, with a modified serum albumin mol-
ecule linking the two. This construct can displace heregulin 
from ErbB3 and thereby prevent its phosphorylation, inhibiting 
tumor growth. Phase 1 clinical studies of MM-111 are currently 
underway, with and without trastuzumab, with which a synergis-
tic effect was found in both in vivo and in vitro studies. It seems 
likely that the two therapeutics target two distinct mechanisms 
of activation within the ErbB network: oncogene activation and 
ligand-induced activation.
The theme of bispecificity was continued by Melvyn Little 
(Affimed Therapeutics), who discussed TandAbs: tetravalent 
antibody-derived constructs 105–110 kDa in length capable of 
binding two epitopes, via two distinct paratopes for each. These 
lack an Fc domain, a feature designed to prevent non-specific 
interaction with immune-effector cells. Clinical studies of an 
anti-CD16A/anti-CD30 TandAb designed to treat Hodgkin 
lymphoma was initiated in October 2010.
Adnectins as a non-antibody-based approach to bispecificity 
was discussed by Eric Furfine (Adnexus/Bristol-Myers Squibb). 
The molecules are targeted therapeutics composed of modified 
human fibronectin subunits. Dr. Furfine described two bispecific 
Adnectins targeting IGFR + anti-EGFR2 and IGFR + VEGFR2 
that are more potent at controlling xenograft tumors expressing 
the relevant receptors than mono-specific constructs. Balancing 
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Mark Sliwkowski (Genentech) provided structural background 
on the mechanisms of action of the anti-HER2 antibodies trastu-
zumab and pertuzumab. While trastuzumab disrupts ligand-inde-
pendent HER2-HER3-PI3K complexes, pertuzumab prevents 
ligand-induced HER2-HER3 dimerization.6 Dr. Sliwkowski 
noted that pertuzumab added meaningful activity comparable to 
a cytotoxic to trastuzumab in a Phase 2 study of HER2+ breast 
cancer patients. A Phase 3 study to evaluate the combination of 
pertuzumab, trastuzumab and docetaxel vs. placebo, trastuzumab 
and docetaxel in previously untreated HER2-positive metastatic 
breast cancer is ongoing.7,8 Dr. Sliwkowski also discussed a promis-
ing example of the classic antibody drug conjugate (ADC) con-
cept, trastuzumab emtansine (T-DM1; Genentech/ImmunoGen), 
which is composed of trastuzumab linked to the cytotoxic drug 
DM1. The ADC is undergoing evaluation in Phase 3 studies, and 
has shown efficacy in patients with HER2-positive MBC who had 
tumor progression after prior treatment with HER2-directed ther-
apy and who had received prior chemotherapy.7,9
Hari Hariharan (Biogen Idec) presented examples of tetra-
valent, bispecific antibodies constructed by fusing scFvs to the 
C-termini of an IgG. “Hercules” is an anti-LTβR/anti-TRAIL-
R2 antibody that agonistically cross-links two TNF family 
receptors.10 The bispecific antibody shows higher in vitro tumor 
cell killing, which is also reflected in superior tumor inhibition 
in a breast tumor xenograft model. BIIB047, an anti-EGFR/
anti-IGF-1R bispecific antibody that simultaneously blocks the 
cross-talking EGFR and IGF-1R pathways, has been shown to 
inhibit cellular activation and has a superior efficacy in a pancre-
atic xenograft model.
As noted by Anna M. Wu (University of California, Los 
Angeles), antibodies are the quintessential molecular-targeted 
agents, both for therapeutics and imaging. Molecular imaging, 
especially immuno positron-emission tomography (PET), allows 
for highly sensitive detection and quantization providing both 
regional and temporal information.
Professor Wu discussed engineered antibodies for molecular 
imaging of cancer. In contrast to therapeutic molecules, antibod-
ies for imaging are engineered to reduce half-life to accelerate 
clearance and remove unwanted background.11 Other objectives 
include improved tissue penetration, removal of all effector func-
tions and conjugation to an image moiety (positron-emitting 
radionuclides such as I-124, Cu-64, F-18). Most suited are rapid 
targeting/rapid clearing fragments such as diabodies12 and mini-
bodies, the former even allowing for same day imaging. The pos-
sibility of generating diabodies from any specificity and routine 
microwave-assisted radiolabeling in microfluidic chips makes 
them a promising class for clinical evaluation. Professor Wu also 
presented work on diabody/human serum albumin fusion con-
structs that may have properties closer to the ideal (i.e., small, 
human, controllable pharmacokinetics).
Christian Klein (Roche Glycart) presented data on GA101 
(RO5072759), a type II, glycoengineered humanized anti-CD20 
monoclonal antibody.13 The company’s technology inhibits anti-
body fucosylation through genetic engineering of the express-
ing cells, resulting in antibodies with higher FcγRIIIa binding, 
increased ADCC, increased direct cell death and reduced CDC. 
the potency of the paired Adnectins and strategies to enhance 
pharmacokinetics by binding Adnectins to serum albumin were 
also discussed
Another potential approach to bispecificity, the CovX-Body, 
was discussed by Venkata Ramana Doppalapudi (Pfizer). This 
approach involves a scaffold antibody that recognizes a reac-
tive mono- or bispecific linker that can covalently bridge the 
paratope and one or more pharmacophores. One such construct, 
CVX-241, utilizes two peptides that recognize Ang-2 and VEGF, 
respectively. It shows better efficacy than mono-specific CovX-
Bodies in tumor xenograft models, and the effect is enhanced 
when CVX-241 is used in combination with chemotherapy.
The final speaker of the morning session was Syd Johnson 
(MacroGenics), who discussed Dual Affinity Re-Targeting 
molecules (DART), an Fv-based platform that incorporates 
disulfide bonds between the C-termini of constructs.3,4 An anti-
CD16+ anti-CD32B DART shows anti-tumor activity, as does 
an anti-HER2+ anti-TCR DART in a bladder cancer xenograft 
model. DARTs are stable for weeks in human serum and can be 
stored for at least two years without loss of viability. Strategies 
for extending the half-life, including Fc and albumin fusions 
were also discussed.
Antibody Engineering for Second- and Third-
Generation Antibody Therapeutics:  
Lessons Learned from the First Generation
Paul Carter (Genentech), chairman of the last session of the con-
ference, emphasized that antibody therapeutics have come of age. 
While their clinical and commercial impact was minimal in the 
1990s, it is substantial today and, consequently, competition is 
intense. The drivers of next-generation therapeutics are diverse: 
(1) there is a clinical need for higher efficacy and safety; (2) prog-
ress in the understanding of biological pathways and networks 
allows for more and diverse targets; (3) engineering technolo-
gies enable the enhancement of intrinsic antibody performance 
(e.g., conjugates, prolonged half-life, modulation of effector 
functions); (4) advances have been made in medical technologies 
(e.g., biomarkers and companion diagnostics, medical device and 
delivery technologies, use of antibodies for imaging); and finally, 
(5) the products are commercially promising.
In discussing attempts to find new drug-sensitive targets, 
Louis M. Weiner (Georgetown University Medical Center) pre-
sented data from a synthetic lethal screen of the central EGFR 
pathway. Out of more than 600 targeted genes, 61 hits that 
define the EGFR “resistance space” were confirmed. This work 
could eventually lead to the development of new treatment strate-
gies based upon knowledge of the genetic determinants of drug 
response. Dr. Weiner also presented data showing that in an 
established HER2+ tumor model high affinity is needed for anti-
bodies that only promote ADCC, and that antibodies promot-
ing ADCC plus signaling perturbation are superior to ADCC 
alone. Finally, new evidence was shown for the “ADCC-mediated 
adaptive immunity switch”5 by a mouse tumor re-challenge study 
where trastuzumab therapy induced powerful T-cell dependent 
HER2-specific adaptive immunity.152  mAbs  Volume 3 Issue 2
Crystallographic studies showed that GA101 binds in a different 
orientation to CD20 than rituximab, which could be responsible 
for the observed differences in stoichiometry and tissue distribu-
tion. GA101 induced stronger inhibition of tumor growth com-
pared with rituximab in preclinical studies.14 GA101 is in clinical 
studies, including two Phase 3 studies in patients with hema-
tological malignancies; it is the most advanced Fc-engineered 
antibody with increased FcγRIIIa binding currently undergoing 
evaluation.
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